<SEC-DOCUMENT>0001193125-22-215050.txt : 20220808
<SEC-HEADER>0001193125-22-215050.hdr.sgml : 20220808
<ACCEPTANCE-DATETIME>20220808171357
ACCESSION NUMBER:		0001193125-22-215050
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220802
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220808
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		221145391

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d345162d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pstv="http://www.plustherapeutics.com/20220802" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2022-08-02_to_2022-08-02">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-08-02_to_2022-08-02">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-08-02_to_2022-08-02">0001095981</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="pstv-20220802.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-08-02_to_2022-08-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-02</xbrli:startDate> <xbrli:endDate>2022-08-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-08-02_to_2022-08-02">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt:datemonthdayyearen">August&#160;2, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-08-02_to_2022-08-02">PLUS THERAPEUTICS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br /></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-08-02_to_2022-08-02">001-34375</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-08-02_to_2022-08-02">33-0827593</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-08-02_to_2022-08-02">4200 Marathon Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-08-02_to_2022-08-02">Suite 200</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-08-02_to_2022-08-02">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-08-02_to_2022-08-02">78756</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, with zip code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-08-02_to_2022-08-02">(737)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-08-02_to_2022-08-02">255-7194</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-08-02_to_2022-08-02">Common Stock, par value $0.001</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-08-02_to_2022-08-02">PSTV</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-08-02_to_2022-08-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On August&#160;2, 2022, Plus Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which Lincoln Park has committed to purchase up to $50&#160;million of the Company&#8217;s common stock, $0.001 par value per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#8217;s common stock (the &#8220;Commitment Amount&#8221;). Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#8217;s sole discretion, over the <span style="white-space:nowrap">36-month</span> period commencing on the date that a registration statement covering the resale of shares of common stock that have been and may be issued under the Purchase Agreement, which the Company agreed to file with the Securities and Exchange Commission (the &#8220;SEC&#8221;) pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions set forth in the Purchase Agreement are satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. There are no upper limits on the price per share that Lincoln Park must pay for shares of common stock. Actual sales of shares of common stock to Lincoln Park will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Company&#8217;s common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. The Company expects that any proceeds received by the Company from such sales to Lincoln Park will be used for working capital and general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On May&#160;16, 2022, the Company held its annual meeting of its stockholders (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company received stockholder approval pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d) to permit issuances of the Company&#8217;s common stock (including the issuance of more than 19.99% of the Company&#8217;s common stock) to Lincoln Park pursuant to the Purchase Agreement. Based on the closing price of the Company&#8217;s common stock of $0.87 per share on January&#160;24, 2022 (the Company&#8217;s lowest closing sale price since January&#160;1, 2022 at the time we filed our proxy statement for the Annual Meeting, as reported on Nasdaq.com) the maximum number of shares the Company could issue and sell under the Purchase Agreement is approximately 57.5&#160;million shares. Accordingly, the Company requested and received stockholder approval for the issuance of up to 57.5&#160;million shares of the Company&#8217;s common stock under the Purchase Agreement. The Company would seek additional stockholder approval before issuing more than 57.5&#160;million shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company has agreed with Lincoln Park that it will not enter into any &#8220;variable rate&#8221; transactions with any third party for a period defined in the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company&#8217;s shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">As consideration for Lincoln Park&#8217;s irrevocable commitment to purchase shares of the Company&#8217;s common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, the Company agreed to pay Lincoln Park an initial commitment fee equal to 1.5% of the Commitment Amount. The initial commitment fee was paid upon execution of the Purchase Agreement through the issuance of 492,698 shares of Common Stock and $125,000. An additional commitment fee equal to 2.5% of the remainder of the Commitment Amount will be paid if and when the Company sells over $25.0&#160;million of the Company&#8217;s common stock under the Purchase Agreement. The additional commitment fee may be paid in cash, Common Stock, or a combination of cash and Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. During any &#8220;event of default&#8221; under the Purchase Agreement, Lincoln Park does not have the right to terminate the Purchase Agreement; however, the Company may not initiate any regular or other purchase of shares by Lincoln Park, until such event of default is cured. In addition, in the event of bankruptcy proceedings by or against the Company, the Purchase Agreement will automatically terminate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Termination of Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with entering into the Purchase Agreement, the prior Purchase Agreement (the &#8220;Agreement&#8221;), dated as of September 30, 2020, by and between the Company and Lincoln Park was terminated effective as of August 2, 2022. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;3.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it is an &#8220;accredited investor&#8221; (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)). The securities referred to in this current report on Form <span style="white-space:nowrap">8-K</span> are being issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration&#160;requirements of the Securities Act afforded by Section&#160;4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits.&#160;&#160;&#160;&#160; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d345162dex101.htm">Purchase Agreement, dated August&#160;2, 2022, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d345162dex102.htm">Registration Rights Agreement, dated August&#160;2, 2022, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&#160;8, 2022 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PLUS THERAPEUTICS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc H. Hedrick, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Office</p></td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d345162dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>PURCHASE AGREEMENT</B> (the &#147;<U>Agreement</U>&#148;), dated as of August&nbsp;2, 2022, by and between <B>PLUS THERAPEUTICS, INC.</B>,
a Delaware corporation (the &#147;<U>Company</U>&#148;), and <B>LINCOLN PARK CAPITAL FUND, LLC</B>, an Illinois limited liability company (the &#147;<U>Investor</U>&#148;). Capitalized terms used herein and not otherwise defined are defined in
Section&nbsp;1 of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy
from the Company, up to Fifty Million Dollars ($50,000,000) of the Company&#146;s common stock, $0.001 par value per share (the &#147;<U>Common Stock</U>&#148;). The shares of Common Stock to be purchased hereunder are referred to herein as the
&#147;<U>Purchase Shares</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement,
and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>CERTAIN DEFINITIONS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) &#147;<U>Accelerated Purchase Date</U>&#148; means, with respect to any Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, the Business Day immediately following the applicable Purchase Date with respect to the corresponding Regular Purchase referred to in clause (i)&nbsp;of the second sentence of
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) &#147;<U>Accelerated Purchase Minimum Price Threshold</U>&#148; means,
with respect to any Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, the greater of (i)&nbsp;seventy-five percent (75%) of the Closing Sale Price of the Common Stock on the applicable Purchase Date with respect to
the corresponding Regular Purchase referred to in clause (i)&nbsp;of the second sentence of <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof and (ii)&nbsp;the minimum per share price threshold set forth in the applicable Accelerated Purchase Notice.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) &#147;<U>Accelerated Purchase Notice</U>&#148; means, with respect to an Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to purchase the number of Purchase Shares specified by the Company therein as the Accelerated Purchase Share Amount
to be purchased by the Investor (such specified Accelerated Purchase Share Amount subject to adjustment in accordance with <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof as necessary to give effect to the Purchase Share amount limitations applicable
to such Accelerated Purchase Share Amount as set forth in this Agreement) at the applicable Accelerated Purchase Price on the applicable Accelerated Purchase Date for such Accelerated Purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) &#147;<U>Accelerated Purchase Price</U>&#148; means, with respect to an Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, <FONT STYLE="white-space:nowrap">ninety-six</FONT> and a half percent (96.5%) of the lower of (i)&nbsp;the VWAP for the period beginning at 9:30:01 a.m., Eastern time, on the applicable Accelerated
Purchase Date, or such other time publicly announced by the Principal Market as the official open (or commencement) of trading on the Principal Market on such applicable Accelerated Purchase Date (the &#147;<U>Accelerated Purchase Commencement
Time</U>&#148;), and ending at the earliest of (A) 4:00:00 p.m., Eastern time, on such applicable Accelerated Purchase Date, or such other time publicly announced by the Principal Market as the official close of trading on the Principal Market on
such applicable Accelerated Purchase Date, (B)&nbsp;such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">total number (or volume) of shares of Common Stock traded on the Principal Market has
exceeded the applicable Accelerated Purchase Share Volume Maximum, and (C)&nbsp;such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the Sale Price has fallen below the applicable Accelerated
Purchase Minimum Price Threshold (such earliest of (i)(A), (i)(B) and (i)(C) above, the &#147;<U>Accelerated Purchase Termination Time</U>&#148;), and (ii)&nbsp;the Closing Sale Price of the Common Stock on such applicable Accelerated Purchase Date
(each to be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) &#147;<U>Accelerated Purchase Share Amount</U>&#148; means, with respect to an Accelerated Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor in an Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 300% of the
number of Purchase Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in clause (i)&nbsp;of the second sentence of
<U>Section</U><U></U><U>&nbsp;2(b)</U> hereof (subject to the Purchase Share limitations contained in <U>Section</U><U></U><U>&nbsp;2(a)</U> hereof) and (ii)&nbsp;an amount equal to (A)&nbsp;the Accelerated Purchase Share Percentage multiplied by
(B)&nbsp;the total number (or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Accelerated Purchase Date beginning at the Accelerated Purchase Commencement Time for such Accelerated Purchase and
ending at the Accelerated Purchase Termination Time for such Accelerated Purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) &#147;<U>Accelerated Purchase Share
Percentage</U>&#148; means, with respect to an Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, thirty percent (30%). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) &#147;<U>Accelerated Purchase Share Volume Maximum</U>&#148; means, with respect to an Accelerated Purchase made pursuant
to <U>Section</U><U></U><U>&nbsp;2(b)</U> hereof, a number of shares of Common Stock equal to (i)&nbsp;the number of Purchase Shares specified by the Company in the applicable Accelerated Purchase Notice as the Accelerated Purchase Share Amount to
be purchased by the Investor in such Accelerated Purchase, divided by (ii)&nbsp;the Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT>
dividend, stock split, reverse stock split or other similar transaction). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) &#147;<U>Additional Accelerated Purchase
Date</U>&#148; means, with respect to an Additional Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, the Business Day (i)&nbsp;that is the Accelerated Purchase Date with respect to the corresponding Accelerated
Purchase referred to in clause (i)&nbsp;of the proviso in the second sentence of<U> Section</U><U></U><U>&nbsp;2(c)</U> hereof and (ii)&nbsp;on which the Investor receives, prior to 1:00 p.m., Eastern time, on such Business Day, a valid Additional
Accelerated Purchase Notice for such Additional Accelerated Purchase in accordance with this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)
&#147;<U>Additional Accelerated Purchase Minimum Price Threshold</U>&#148; means, with respect to an Additional Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, the greater of (i)&nbsp;seventy-five percent (75%)
of the Closing Sale Price of the Common Stock on the Business Day immediately preceding the applicable Additional Accelerated Purchase Date with respect to such Additional Accelerated Purchase and (ii)&nbsp;the minimum per share price threshold set
forth in the applicable Additional Accelerated Purchase Notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) &#147;<U>Additional Accelerated Purchase
Notice</U>&#148; means, with respect to an Additional Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to purchase the number
of Purchase Shares specified by the Company therein as the Additional Accelerated Purchase Share Amount to be purchased by the Investor (such specified Additional Accelerated Purchase Share Amount subject to adjustment in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
accordance with <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof as necessary to give effect to the Purchase Share amount limitations applicable to such Additional Accelerated Purchase Share Amount
as set forth in this Agreement) at the applicable Additional Accelerated Purchase Price on the applicable Additional Accelerated Purchase Date for such Additional Accelerated Purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) &#147;<U>Additional Accelerated Purchase Price</U>&#148; means, with respect to an Additional Accelerated Purchase made
pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, <FONT STYLE="white-space:nowrap">ninety-six</FONT> and a half percent (96.5%) of the lower of (i)&nbsp;the VWAP for the period on the applicable Additional Accelerated Purchase Date,
beginning at the latest of (A)&nbsp;the applicable Accelerated Purchase Termination Time with respect to the corresponding Accelerated Purchase referred to in clause (i)&nbsp;of the proviso in the second sentence of
<U>Section</U><U></U><U>&nbsp;2(c)</U> hereof on such Additional Accelerated Purchase Date, (B)&nbsp;the applicable Additional Accelerated Purchase Termination Time with respect to the most recently completed prior Additional Accelerated Purchase on
such Additional Accelerated Purchase Date, as applicable, and (C)&nbsp;the time at which all Purchase Shares subject to all prior Accelerated Purchases and Additional Accelerated Purchases (as applicable), including, without limitation, those that
have been effected on the same Business Day as the applicable Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, have theretofore been received by the Investor as DWAC Shares in
accordance with this Agreement (such latest of (i)(A), (i)(B) and (i)(C) above, the &#147;<U>Additional Accelerated Purchase Commencement Time</U>&#148;), and ending at the earliest of (X) 4:00 p.m., Eastern time, on such Additional Accelerated
Purchase Date, or such other time publicly announced by the Principal Market as the official close of trading on the Principal Market on such Additional Accelerated Purchase Date, (Y)&nbsp;such time, from and after the Additional Accelerated
Purchase Commencement Time for such Additional Accelerated Purchase, that the total number (or volume) of shares of Common Stock traded on the Principal Market has exceeded the applicable Additional Accelerated Purchase Share Volume Maximum, and
(Z)&nbsp;such time, from and after the Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase, that the Sale Price has fallen below the applicable Additional Accelerated Purchase Minimum Price Threshold (such
earliest of (i)(X), (i)(Y) and (i)(Z) above, the &#147;<U>Additional Accelerated Purchase Termination Time</U>&#148;), and (ii)&nbsp;the Closing Sale Price of the Common Stock on such Additional Accelerated Purchase Date (each to be appropriately
adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) &#147;<U>Additional Accelerated Purchase Share Amount</U>&#148; means, with respect to an Additional Accelerated Purchase
made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, the number of Purchase Shares directed by the Company to be purchased by the Investor on an Additional Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the
lesser of (i) 300% of the number of Purchase Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in clause (i)&nbsp;of the proviso in
the second sentence of <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof (subject to the Purchase Share limitations contained in <U>Section</U><U></U><U>&nbsp;2(a)</U> hereof) and (ii)&nbsp;an amount equal to (A)&nbsp;the Additional Accelerated Purchase
Share Percentage multiplied by (B)&nbsp;the total number (or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Additional Accelerated Purchase Date beginning at the Additional Accelerated Purchase
Commencement Time for such Additional Accelerated Purchase and ending at the Additional Accelerated Purchase Termination Time for such Additional Accelerated Purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m) &#147;<U>Additional Accelerated Purchase Share Percentage</U>&#148; means, with respect to an Additional Accelerated
Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, thirty percent (30%). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n) &#147;<U>Additional
Accelerated Purchase Share Volume Maximum</U>&#148; means, with respect to an Additional Accelerated Purchase made pursuant to <U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, a number of shares of Common Stock equal to (i)&nbsp;the number of Purchase
Shares specified by the Company in the applicable Additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Accelerated Purchase Notice as the Additional Accelerated Purchase Share Amount to be purchased by the Investor in such Additional Accelerated Purchase, divided by (ii)&nbsp;the Additional
Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(o) &#147;<U>Alternate Adjusted Regular Purchase Share Limit</U>&#148; means, with respect to a Regular Purchase made pursuant
to <U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, the maximum number of Purchase Shares which, taking into account the applicable per share Purchase Price therefor calculated in accordance with this Agreement, would enable the Company to deliver to
the Investor, on the applicable Purchase Date for such Regular Purchase, a Regular Purchase Notice for a Purchase Amount equal to, or as closely approximating without exceeding, One Hundred Fifty Thousand Dollars ($150,000). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(p) &#147;<U>Available Amount</U>&#148; means, initially, Fifty Million Dollars ($50,000,000) in the aggregate, which amount
shall be reduced by the Purchase Amount each time the Investor purchases Purchase Shares pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(q) &#147;<U>Average Price</U>&#148; means a price per Purchase Share (rounded to the nearest tenth of a cent) equal to the
quotient obtained by dividing (i)&nbsp;the aggregate gross purchase price paid by the Investor for all Purchase Shares purchased pursuant to this Agreement, by (ii)&nbsp;the aggregate number of Purchase Shares issued pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(r) &#147;<U>Bankruptcy Law</U>&#148; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(s) &#147;<U>Business Day</U>&#148; means any day on which the Principal Market is open for trading, including any day on
which the Principal Market is open for trading for a period of time less than the customary time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(t) &#147;<U>Closing
Sale Price</U>&#148; means, for any security as of any date, the last closing sale price for such security on the Principal Market as reported by the Principal Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(u) &#147;<U>Commitment Shares</U>&#148; means, collectively, the Initial Commitment Shares (as defined in
<U>Section</U><U></U><U>&nbsp;5(e) </U>hereof) and the Additional Commitment Shares (as defined in <U>Section</U><U></U><U>&nbsp;5(e) </U>hereof). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) &#147;<U>Confidential Information</U>&#148; means any information disclosed by either party to the other party, either
directly or indirectly, in writing, orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment), which is designated as &#147;Confidential,&#148; &#147;Proprietary&#148; or some
similar designation. Information communicated orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information within ten (10)&nbsp;Business Days after the initial disclosure.
Confidential Information may also include information disclosed to a disclosing party by third parties. Confidential Information shall not, however, include any information which (i)&nbsp;was publicly known and made generally available in the public
domain prior to the time of disclosure by the disclosing party; (ii)&nbsp;becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party;
(iii)&nbsp;is already in the possession of the receiving party without confidential restriction at the time of disclosure by the disclosing party as shown by the receiving party&#146;s files and records immediately prior to the time of disclosure;
(iv)&nbsp;is obtained by the receiving party from a third party without a breach of such third party&#146;s obligations of confidentiality; (v)&nbsp;is independently developed by the receiving party without use of or reference to the disclosing
party&#146;s Confidential Information, as shown by documents and other competent evidence in the receiving party&#146;s possession; or (vi)&nbsp;is required by law to be disclosed by the receiving party, provided that the receiving party gives the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(w) &#147;<U>Custodian</U>&#148; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy
Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) &#147;<U>DTC</U>&#148; means The Depository Trust Company, or any successor performing substantially the same
function for the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(y) &#147;<U>DWAC Shares</U>&#148; means shares of Common Stock that are (i)&nbsp;issued in
electronic form, (ii)&nbsp;freely tradable and transferable and without restriction on resale and (iii)&nbsp;timely credited by the Company to the Investor&#146;s or its designee&#146;s specified Deposit/Withdrawal at Custodian (DWAC) account with
DTC under its Fast Automated Securities Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(z) &#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(aa) &#147;<U>Floor Price</U>&#148; means, with respect to a Regular Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, $0.25, which shall be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction and, effective
upon the consummation of any such reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction, the Floor Price shall mean the <U>lower</U> of (i)&nbsp;the adjusted price and
(ii) $1.00. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(bb) &#147;<U>Fully Adjusted Regular Purchase Share Limit</U>&#148; means, with respect to any reorganization,
recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction from and after the date of this Agreement, the Regular Purchase Share Limit (as defined in <U>Section</U><U></U><U>&nbsp;2(a)
</U>hereof) in effect on the applicable date of determination, after giving effect to the full proportionate adjustment thereto made pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> hereof for or in respect of such reorganization,
recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(cc) &#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on (i)&nbsp;the enforceability of any
Transaction Document, (ii)&nbsp;the results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any material adverse effect that resulted exclusively from (A)&nbsp;any change in
the United States or foreign economies or securities or financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B)&nbsp;any change that generally affects the industry in which
the Company and its Subsidiaries operate that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (C)&nbsp;any change arising in connection with earthquakes, hostilities, acts of war, sabotage or terrorism
or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions existing as of the date hereof, (D)&nbsp;any action taken by the Investor, its affiliates or its or their
successors and assigns with respect to the transactions contemplated by this Agreement, (E)&nbsp;the effect of any change in applicable laws or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries, taken
as a whole, or (F)&nbsp;any change resulting from compliance with terms of this Agreement or the consummation of the transactions contemplated by this Agreement, or (iii)&nbsp;the Company&#146;s ability to perform in any material respect on a timely
basis its obligations under any Transaction Document to be performed as of the date of determination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(dd)
&#147;<U>Maturity Date</U>&#148; means the first day of the month immediately following the <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;month anniversary of the Commencement Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ee) &#147;<U>PEA Period</U>&#148; means the period commencing at 9:30 a.m.,
Eastern time, on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day immediately prior to the filing of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement (as
such term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern time, on the Business Day immediately following, the effective date of any post-effective amendment to the Registration Statement (as defined herein) or New
Registration Statement (as such term is defined in the Registration Rights Agreement). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ff) &#147;<U>Person</U>&#148;
means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(gg) &#147;<U>Principal Market</U>&#148; means The Nasdaq Capital Market (or any nationally recognized successor thereto);
provided, however, that in the event the Company&#146;s Common Stock is ever listed or traded on The Nasdaq Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, the OTC Bulletin Board, or the
OTCQX or OTCQB operated by OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing), then the &#147;Principal Market&#148; shall mean such other market or exchange on which the Company&#146;s Common Stock is then
listed or traded. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(hh) &#147;<U>Purchase Amount</U>&#148; means, with respect to any Regular Purchase, any Accelerated
Purchase or any Additional Accelerated Purchase made hereunder, as applicable, the portion of the Available Amount to be purchased by the Investor pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) &#147;<U>Purchase Date</U>&#148; means, with respect to a Regular Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, the Business Day on which the Investor receives, after 4:00 p.m., Eastern time, but prior to 5:00 p.m., Eastern time, on such Business Day, a valid Regular Purchase Notice for such Regular Purchase in
accordance with this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(jj) &#147;<U>Purchase Notice</U>&#148; means a Regular Purchase Notice, an Accelerated
Purchase Notice or an Additional Accelerated Purchase Notice with respect to any Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(kk) &#147;<U>Purchase Price</U>&#148; means, with respect to any Regular Purchase made pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, the lower of: (i)&nbsp;the lowest Sale Price on the applicable Purchase Date for such Regular Purchase and (ii)&nbsp;the arithmetic average of the three (3)&nbsp;lowest Closing Sale Prices for the
Common Stock during the ten (10)&nbsp;consecutive Business Days ending on the Business Day immediately preceding such Purchase Date for such Regular Purchase (in each case, to be appropriately adjusted for any reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction that occurs on or after the date of this Agreement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ll) &#147;<U>Regular Purchase Notice</U>&#148; means, with respect to any Regular Purchase pursuant to
<U>Section</U><U></U><U>&nbsp;2(a)</U> hereof, an irrevocable written notice from the Company to the Investor directing the Investor to buy such applicable amount of Purchase Shares at the applicable Purchase Price as specified by the Company
therein on the applicable Purchase Date for such Regular Purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(mm) &#147;<U>Sale Price</U>&#148; means any trade
price for the shares of Common Stock on the Principal Market as reported by the Principal Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(nn)
&#147;<U>SEC</U>&#148; means the U.S. Securities and Exchange Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(oo) &#147;<U>Securities</U>&#148; means, collectively, the Purchase Shares
and the Commitment Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(pp) &#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(qq) &#147;<U>Subsidiary</U>&#148; means any Person the Company wholly-owns
or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(rr) &#147;<U>Transaction
Documents</U>&#148; means, collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement and the schedules and exhibits thereto, and each of the other agreements, documents, certificates and instruments
entered into or furnished by the parties hereto in connection with the transactions contemplated hereby and thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ss)
&#147;<U>Transfer Agent</U>&#148; means Computershare Inc., or such other Person who is then serving as the transfer agent for the Company in respect of the Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(tt) &#147;<U>VWAP</U>&#148; means in respect of an Accelerated Purchase Date and an Additional Accelerated Purchase Date, as
applicable, the volume weighted average price of the Common Stock on the Principal Market, as reported on the Principal Market or by another reputable source such as Bloomberg, L.P. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>PURCHASE OF COMMON STOCK. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the terms and conditions set forth in this Agreement, the Company has the right to sell to the Investor, in the
Company&#146;s sole and absolute discretion, and the Investor has the obligation to purchase from the Company, Purchase Shares as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Commencement of Regular Sales of Common Stock</U>. Upon the satisfaction of all of the conditions set forth in
<U>Sections 7</U> and <U>8</U> hereof (the &#147;<U>Commencement</U>&#148; and the date of satisfaction of such conditions the &#147;<U>Commencement Date</U>&#148;) and thereafter, the Company shall have the right, but not the obligation, to direct
the Investor, by its delivery to the Investor of a Regular Purchase Notice from time to time, to purchase up to One Hundred Thousand (100,000) Purchase Shares, subject to adjustment as set forth below in this <U>Section</U><U></U><U>&nbsp;2(a)</U>
(such maximum number of Purchase Shares, as may be adjusted from time to time, the &#147;<U>Regular Purchase Share Limit</U>&#148;), at the Purchase Price on the Purchase Date (each such purchase a &#147;<U>Regular Purchase</U>&#148;);
<U>provided</U>, <U>however</U>, that (i)&nbsp;the Regular Purchase Share Limit shall be increased to up to Two Hundred Thousand (200,000) Purchase Shares, if the Closing Sale Price of the Common Stock on the applicable Purchase Date is not below
$2.00, and (ii)&nbsp;the Regular Purchase Share Limit shall be increased to up to Three Hundred Thousand (300,000) Purchase Shares, if the Closing Sale Price of the Common Stock on the applicable Purchase Date is not below $3.00 (all of which share
and dollar amounts shall be appropriately proportionately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction; <U>provided</U> that if, after giving
effect to the full proportionate adjustment to the Regular Purchase Share Limit therefor, the Fully Adjusted Regular Purchase Share Limit then in effect would preclude the Company from delivering to the Investor a Regular Purchase Notice hereunder
for a Purchase Amount (calculated by multiplying (X)&nbsp;the number of Purchase Shares equal to the Fully Adjusted Regular Purchase Share Limit, by (Y)&nbsp;the Purchase Price per Purchase Share covered by such Regular Purchase Notice on the
applicable Purchase Date therefor) equal to or greater than One Hundred Fifty Thousand Dollars ($150,000), the Regular Purchase Share Limit for such Regular Purchase Notice shall not be fully adjusted to equal the applicable Fully Adjusted Regular
Purchase Share Limit, but rather the Regular Purchase Share Limit for such Regular Purchase Notice shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be adjusted to equal the applicable Alternate Adjusted Regular Purchase Share Limit as of the applicable Purchase Date for such Regular Purchase Notice); and <U>provided</U>, <U>further</U>,
<U>however</U>, that the Investor&#146;s committed obligation under any single Regular Purchase, other than any Regular Purchase with respect to which an Alternate Adjusted Regular Purchase Share Limit shall apply, shall not exceed One Million
Dollars ($1,000,000). If the Company delivers any Regular Purchase Notice for a Purchase Amount in excess of the limitations contained in the immediately preceding sentence, such Regular Purchase Notice shall be void <I>ab initio</I> to the extent
of the amount by which the number of Purchase Shares set forth in such Regular Purchase Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Purchase Notice in accordance herewith, and the Investor shall
have no obligation to purchase such excess Purchase Shares in respect of such Regular Purchase Notice; <U>provided</U>, <U>however</U>, that the Investor shall remain obligated to purchase the number of Purchase Shares which the Company is permitted
to include in such Regular Purchase Notice. The Company may deliver a Regular Purchase Notice to the Investor as often as every Business Day, so long as (i)&nbsp;the Closing Sale Price of the Common Stock on such Business Day is not less than the
Floor Price and (ii)&nbsp;all Purchase Shares subject to all prior Regular Purchases, and all Additional Commitment Shares issuable in respect thereof pursuant to <U>Section</U><U></U><U>&nbsp;5(e)</U>, have theretofore been received by the Investor
as DWAC Shares in accordance with this Agreement. Notwithstanding the foregoing, the Company shall not deliver any Regular Purchase Notices to the Investor during the PEA Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Accelerated Purchases</U>. Subject to the terms and conditions of this Agreement, from and after the Commencement Date,
in addition to purchases of Purchase Shares as described in <U>Section</U><U></U><U>&nbsp;2(a)</U> above, the Company shall also have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of an Accelerated
Purchase Notice from time to time in accordance with this Agreement, to purchase the applicable Accelerated Purchase Share Amount at the Accelerated Purchase Price on the Accelerated Purchase Date therefor in accordance with this Agreement (each
such purchase, an &#147;<U>Accelerated Purchase</U>&#148;). The Company may deliver an Accelerated Purchase Notice to the Investor only (i)&nbsp;on a Purchase Date on which the Company also properly submitted a Regular Purchase Notice providing for
a Regular Purchase of a number of Purchase Shares not less than the Regular Purchase Share Limit then in effect on such Purchase Date in accordance with this Agreement (including, without limitation, giving effect to any automatic increase to the
Regular Purchase Share Limit as a result of the Closing Sale Price of the Common Stock exceeding certain thresholds set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U> above on such Purchase Date and any other adjustments to the Regular Purchase
Share Limit, in each case pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> above) and (ii)&nbsp;if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases effected prior to the Regular
Purchase Date referred to in clause (i)&nbsp;hereof (as applicable), and all Additional Commitment Shares issuable in respect thereof pursuant to <U>Section</U><U></U><U>&nbsp;5(e)</U>, have theretofore been received by the Investor as DWAC Shares
in accordance with this Agreement. If the Company delivers any Accelerated Purchase Notice directing the Investor to purchase an amount of Purchase Shares that exceeds the Accelerated Purchase Share Amount that the Company is then permitted to
include in such Accelerated Purchase Notice, such Accelerated Purchase Notice shall be void <I>ab initio</I> to the extent of the amount by which the number of Purchase Shares set forth in such Accelerated Purchase Notice exceeds the Accelerated
Purchase Share Amount that the Company is then permitted to include in such Accelerated Purchase Notice (which shall be confirmed in an Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such excess Purchase
Shares in respect of such Accelerated Purchase Notice; <U>provided</U>, <U>however</U>, that the Investor shall remain obligated to purchase the Accelerated Purchase Share Amount which the Company is permitted to include in such Accelerated Purchase
Notice. Within one (1)&nbsp;Business Day after completion of each Accelerated Purchase Date for an Accelerated Purchase, the Investor will provide to the Company a written confirmation of such Accelerated Purchase setting forth the applicable
Accelerated Purchase Share Amount and Accelerated Purchase Price for such Accelerated Purchase (each, an &#147;<U>Accelerated Purchase Confirmation</U>&#148;). Notwithstanding the foregoing, the Company shall not deliver any Accelerated Purchase
Notices to the Investor during the PEA Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Additional Accelerated Purchases</U>. Subject to the terms and
conditions of this Agreement, from and after the Commencement Date, in addition to purchases of Purchase Shares as described in <U>Section</U><U></U><U>&nbsp;2(a)</U> and <U>Section</U><U></U><U>&nbsp;2(b)</U> above, the Company shall also have the
right, but not the obligation, to direct the Investor, by its timely delivery to the Investor of an Additional Accelerated Purchase Notice on an Additional Accelerated Purchase Date in accordance with this Agreement, to purchase the applicable
Additional Accelerated Purchase Share Amount at the applicable Additional Accelerated Purchase Price therefor in accordance with this Agreement (each such purchase, an &#147;<U>Additional Accelerated Purchase</U>&#148;). The Company may deliver
multiple Additional Accelerated Purchase Notices to the Investor on an Additional Accelerated Purchase Date; <U>provided</U>, <U>however</U>, that the Company may deliver an Additional Accelerated Purchase Notice to the Investor only (i)&nbsp;on a
Business Day that is also the Accelerated Purchase Date for an Accelerated Purchase with respect to which the Company properly submitted to the Investor an Accelerated Purchase Notice in accordance with this Agreement on the applicable Purchase Date
for a Regular Purchase of a number of Purchase Shares not less than the Regular Purchase Share Limit then in effect in accordance with this Agreement (including, without limitation, giving effect to any automatic increase to the Regular Purchase
Share Limit as a result of the Closing Sale Price of the Common Stock exceeding certain thresholds set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U> above on such Purchase Date and any other adjustments to the Regular Purchase Share Limit, in each
case pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> above), and (ii)&nbsp;if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, including, without limitation, those that have
been effected on the same Business Day as the applicable Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates (as applicable), and all Additional Commitment Shares issuable in respect
thereof pursuant to <U>Section</U><U></U><U>&nbsp;5(e)</U>, in each case have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement. If the Company delivers any Additional Accelerated Purchase Notice directing
the Investor to purchase an amount of Purchase Shares that exceeds the Additional Accelerated Purchase Share Amount that the Company is then permitted to include in such Additional Accelerated Purchase Notice, such Additional Accelerated Purchase
Notice shall be void <I>ab initio</I> to the extent of the amount by which the number of Purchase Shares set forth in such Additional Accelerated Purchase Notice exceeds the Additional Accelerated Purchase Share Amount that the Company is then
permitted to include in such Additional Accelerated Purchase Notice (which shall be confirmed in an Additional Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such
Additional Accelerated Purchase Notice; <U>provided</U>, <U>however</U>, that the Investor shall remain obligated to purchase the Additional Accelerated Purchase Share Amount which the Company is permitted to include in such Additional Accelerated
Purchase Notice. Within one (1)&nbsp;Business Day after completion of each Additional Accelerated Purchase Date, the Investor will provide to the Company a written confirmation of each Additional Accelerated Purchase on such Additional Accelerated
Purchase Date setting forth the applicable Additional Accelerated Purchase Share Amount and Additional Accelerated Purchase Price for each such Additional Accelerated Purchase on such Additional Accelerated Purchase Date (each, an
&#147;<U>Additional Accelerated Purchase Confirmation</U>&#148;). Notwithstanding the foregoing, the Company shall not deliver any Additional Accelerated Purchase Notices to the Investor during the PEA Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Payment for Purchase Shares.</U> For each Regular Purchase, the Investor shall pay to the Company an amount equal to the
Purchase Amount with respect to such Regular Purchase as full payment for such Purchase Shares via wire transfer of immediately available funds on the same Business Day that the Investor receives such Purchase Shares, if such Purchase Shares are
received by the Investor before 1:00 p.m., Eastern time, or, if such Purchase Shares are received by the Investor after 1:00 p.m., Eastern time, the next Business Day. For each Accelerated Purchase and each Additional Accelerated Purchase, the
Investor shall pay to the Company an amount equal to the Purchase Amount with respect to such Accelerated Purchase and Additional Accelerated Purchase, respectively, as full payment for such Purchase Shares via wire transfer of immediately available
funds on the second Business Day following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the date that the Investor receives such Purchase Shares. If the Company or the Transfer Agent shall fail for any reason or for no reason to electronically transfer any Purchase Shares as DWAC
Shares in respect of a Regular Purchase, an Accelerated Purchase or an Additional Accelerated Purchase (as applicable) within two (2)&nbsp;Business Days following the receipt by the Company of the Purchase Price, Accelerated Purchase Price and
Additional Accelerated Purchase Price, respectively, therefor in compliance with this <U>Section</U><U></U><U>&nbsp;2(d)</U>, and if on or after such Business Day the Investor purchases (in an open market transaction or otherwise) shares of Common
Stock to deliver in satisfaction of a sale by the Investor of such Purchase Shares that the Investor anticipated receiving from the Company in respect of such Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase (as applicable),
then the Company shall, within two (2)&nbsp;Business Days after the Investor&#146;s request, either (i)&nbsp;pay cash to the Investor in an amount equal to the Investor&#146;s total purchase price (including customary brokerage commissions, if any)
for the shares of Common Stock so purchased (the &#147;<U>Cover Price</U>&#148;), at which point the Company&#146;s obligation to deliver such Purchase Shares as DWAC Shares shall terminate, or (ii)&nbsp;promptly honor its obligation to deliver to
the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the Cover Price over the total Purchase Amount paid by the Investor pursuant to this Agreement for all of the Purchase Shares
to be purchased by the Investor in connection with such Regular Purchase, Accelerated Purchase and Additional Accelerated Purchase (as applicable). The Company shall not issue any fraction of a share of Common Stock upon any Regular Purchase,
Accelerated Purchase or Additional Accelerated Purchase. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up or down to the nearest whole share.
All payments made under this Agreement shall be made in lawful currency of the United States of America by wire transfer of immediately available funds to such account as the Company may from time to time designate by written notice in accordance
with the provisions of this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding day that is a Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Compliance with Rules of Principal Market</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Maximum Share Cap</U>. The Company shall not issue or sell any shares of Common Stock pursuant to this Agreement, and
the Investor shall not purchase or acquire any shares of Common Stock pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number of shares of Common Stock that would be issued pursuant to this Agreement and the
transactions contemplated hereby would exceed 57,500,000, which number of shares shall be appropriately adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar
transaction that occurs after the date of this Agreement (such maximum number of shares, the &#147;<U>Maximum Share Cap</U>&#148;), unless and until the Company elects to solicit stockholder approval of the issuance of Common Stock as contemplated
by this Agreement, and the stockholders of the Company have in fact approved the issuance of Common Stock as contemplated by this Agreement in accordance with the applicable rules of The Nasdaq Stock Market. For the avoidance of doubt, the Company
may, but shall be under no obligation to, request its stockholders to approve the issuance of Common Stock as contemplated by this Agreement; provided, that if stockholder approval is not obtained in accordance with this
<U>Section</U><U></U><U>&nbsp;2(e)(i)</U>, the Maximum Share Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all times during the term of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>General</U>. The Company shall not issue any shares of Common Stock pursuant to this Agreement if such issuance would
reasonably be expected to result in (A)&nbsp;a violation of the Securities Act or (B)&nbsp;a breach of the rules and regulations of The Nasdaq Stock Market. The provisions of this <U>Section</U><U></U><U>&nbsp;2(e)</U> shall be implemented in a
manner otherwise than in strict conformity with the terms hereof only if necessary to ensure compliance with the Securities Act and the rules and regulations of The Nasdaq Stock Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>Beneficial Ownership Limitation.</U> Notwithstanding anything to the
contrary contained in this Agreement, the Company shall not&nbsp;issue or sell, and the Investor shall not&nbsp;purchase or acquire, any shares of Common Stock under this Agreement&nbsp;which, when aggregated with all other shares of Common Stock
then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in the beneficial ownership by
the&nbsp;Investor&nbsp;of more than&nbsp;4.99% of the then issued and outstanding shares of Common Stock (the &#147;<U>Beneficial Ownership Limitation</U>&#148;). Upon the written or oral request of the Investor, the Company shall promptly (but not
later than 24 hours) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required hereby and the application
hereof. The Investor&#146;s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and
such result absent manifest error. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>INVESTOR&#146;S REPRESENTATIONS AND WARRANTIES. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Organization and Authority</U>. The Investor is an entity duly organized, validly existing and in good standing under
the laws of the jurisdiction of its organization, with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Investment Purpose</U>. The Investor is acquiring the Securities as principal for its own account and not with a view to
or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any
applicable state securities law and has no direct or indirect arrangement or understandings with any other Persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting the Investor&#146;s right to sell the Securities at any time pursuant to the Registration Statement described herein or otherwise in compliance with applicable federal and state securities
laws).&nbsp;The Investor is acquiring the Securities hereunder in the ordinary course of its business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Accredited
Investor Status</U>. The Investor is an &#147;accredited investor&#148; as that term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Reliance on Exemptions</U>. The Investor understands that the Securities are being offered and sold to it in reliance on
specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the Investor&#146;s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the Investor to acquire the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Information</U>. The Investor understands that its investment in the Securities involves a high degree of risk. The
Investor (i)&nbsp;is able to bear the economic risk of an investment in the Securities including a total loss thereof, (ii)&nbsp;has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and
risks of the proposed investment in the Securities and (iii)&nbsp;has had an opportunity to ask questions of and receive answers from the officers of the Company concerning the financial condition and business of the Company and other matters
related to an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
investment in the Securities. Neither such inquiries nor any other due diligence investigations conducted by the Investor or its representatives shall modify, amend or affect the Investor&#146;s
right to rely on the Company&#146;s representations and warranties contained in <U>Section</U><U></U><U>&nbsp;4</U> below. The Investor has sought such accounting, legal and tax advice from its own independent advisors as it has considered necessary
to make an informed investment decision with respect to its acquisition of the Securities and is not relying on any accounting, legal, tax or other advice from the Company or its officers, employees, representatives or advisors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>No Governmental Review</U>. The Investor understands that no U.S. federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of an investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <U>Transfer or Sale</U>. The Investor understands that (i)&nbsp;the Securities may not be offered for
sale, sold, assigned or transferred unless (A)&nbsp;registered pursuant to the Securities Act or (B)&nbsp;an exemption exists permitting such Securities to be sold, assigned or transferred without such registration; (ii)&nbsp;any sale of the
Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale
is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) <U>Validity; Enforcement</U>. This Agreement has been duly and validly authorized, executed and delivered on behalf of the
Investor and is a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms, subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&#146; rights and remedies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Residency</U>. The Investor is a resident of the State of Illinois. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) <U>No Short Selling</U>. The Investor represents and warrants to the Company that at no time prior to the date of this
Agreement has any of the Investor, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) &#147;short sale&#148; (as such term is defined in Rule 200 of Regulation SHO of the
Exchange Act) of the Common Stock or (ii)&nbsp;hedging transaction, which establishes a net short position with respect to the Common Stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company represents and warrants to the Investor that, except as set forth in the disclosure schedules attached hereto,
which exceptions shall be deemed to be a part of the representations and warranties made hereunder, as of the date hereof and as of the Commencement Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Organization and Qualification</U>. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as
currently conducted.&nbsp;Neither the Company nor any of its Subsidiaries is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.&nbsp;Each
of the Company and its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such
qualification necessary, except where the failure to be so qualified or in good standing, as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or
seeking to revoke, limit or curtail such power and authority or qualification. The Company has no Subsidiaries except as set forth on Exhibit 21.1 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Authorization; Enforcement; Validity</U>. (i)&nbsp;The Company has the requisite
corporate power and authority to enter into and perform its obligations under this Agreement, the Registration Rights Agreement and each of the other Transaction Documents, and to issue the Securities in accordance with the terms hereof and thereof,
(ii)&nbsp;the execution and delivery of the Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the Initial Commitment Shares and the
reservation for issuance and the issuance of the Additional Commitment Shares and the Purchase Shares issuable under this Agreement, have been duly authorized by the Company&#146;s Board of Directors and no further consent or authorization is
required by the Company, its Board of Directors or its stockholders (except as provided in this Agreement), (iii) each of this Agreement and the Registration Rights Agreement has been, and each other Transaction Document shall be on the Commencement
Date, duly executed and delivered by the Company and (iv)&nbsp;each of this Agreement and the Registration Rights Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and
binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement of creditors&#146; rights and remedies. The Board of Directors of the Company has adopted resolutions by written consent which authorize this Agreement, the
Registration Rights Agreement and the transactions contemplated hereby (the &#147;<U>Signing Resolutions&#148;)</U>. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented in any respect. The Company
has delivered to the Investor a true and correct copy of minutes of a meeting of the Board of Directors of the Company at which the Signing Resolutions were duly adopted by the Board of Directors or a unanimous written consent adopting the Signing
Resolutions executed by all of the members of the Board of Directors of the Company. At the 2022 Annual Meeting of Stockholders of the Company duly called and held on May&nbsp;16, 2022, (i) the Board of Directors of the Company unanimously
recommended to the Company&#146;s stockholders that they vote to approve the issuance of shares of Common Stock up to the Maximum Share Cap by the Company to the Investor under this Agreement, and (ii)&nbsp;the issuance of shares of Common Stock up
to the Maximum Share Cap by the Company to the Investor under this Agreement was duly approved by the stockholders of the Company at the 2022 Annual Meeting of Stockholders by the affirmative vote of a majority of the votes cast by the stockholders
of the Company present in person or by proxy and entitled to vote at the 2022 Annual Meeting of Stockholders, in accordance with applicable law, the Certificate of Incorporation, the Bylaws, and the applicable rules of the Principal Market (the
&#147;<U>Stockholders&#146; Approval</U>&#148;). Except as set forth in this Agreement, no other approvals or consents of the Company&#146;s Board of Directors, any authorized committee thereof, or stockholders (except as provided in this Agreement)
is necessary under applicable laws, the Certificate of Incorporation, the Bylaws or the applicable rules of the Principal Market to authorize the execution and delivery of the Transaction Documents or any of the transactions contemplated thereby,
including, but not limited to, the issuance of Securities up to the Maximum Share Cap. The Company has delivered to the Investor a true, correct and complete copy of the report of the inspector of elections of the 2022 Annual Meeting of Stockholders
of the Company at which the Stockholders&#146; Approval was obtained. The Stockholders&#146; Approval is valid, in full force and effect and has not been modified or supplemented in any respect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Capitalization</U>. As of the date hereof, the authorized capital stock of the Company is set forth in the
Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022. Except as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
disclosed in the SEC Documents (as defined below), (i) no shares of the Company&#146;s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances
suffered or permitted by the Company, (ii)&nbsp;there are no outstanding debt securities, (iii)&nbsp;except pursuant to equity incentive or stock purchase plans disclosed in the SEC Documents, there are no outstanding options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of
any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, (iv)&nbsp;except pursuant to equity incentive or stock purchase plans disclosed in the SEC
Documents, there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the Securities Act (except the Registration Rights Agreement), (v) there are no
outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi)&nbsp;there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the
Securities as described in this Agreement and (vii)&nbsp;the Company does not have any stock appreciation rights or &#147;phantom stock&#148; plans or agreements or any similar plan or agreement. The Company has furnished to the Investor true and
correct copies of the Company&#146;s Certificate of Incorporation, as amended and as in effect on the date hereof (the &#147;<U>Certificate of Incorporation</U>&#148;), and the Company&#146;s Bylaws, as amended and as in effect on the date hereof
(the &#147;<U>Bylaws</U>&#148;), and summaries of the material terms of all securities convertible into or exercisable for Common Stock, if any, and copies of any documents containing the material rights of the holders thereof in respect thereto
that are not disclosed in the SEC Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Issuance of Securities</U>. Upon issuance and payment therefor in
accordance with the terms and conditions of this Agreement, the Purchase Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights with respect
to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. Upon issuance in accordance with the terms and conditions of this Agreement, the Commitment Shares shall be validly issued, fully paid and
nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. 14,036,665
shares of Common Stock have been duly authorized and reserved for issuance upon purchase under this Agreement as Purchase Shares. 963,335 shares of Common Stock have been duly authorized and reserved for issuance as Additional Commitment Shares in
accordance with this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>No Conflicts</U>. The execution, delivery and performance of the Transaction
Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Initial Commitment Shares and the reservation for issuance and issuance of the
Purchase Shares and the Additional Commitment Shares) will not (i)&nbsp;result in a violation of the Certificate of Incorporation, any Certificate of Designations, Preferences and Rights of any outstanding series of preferred stock of the Company or
the Bylaws or (ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the
rules and regulations of the Principal Market applicable to the Company or any of its Subsidiaries) or by which any property or asset of the Company or any of its Subsidiaries is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
bound or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations, cancellations and violations under clause (ii), which could not reasonably be expected to
result in a Material Adverse Effect. Neither the Company nor its Subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, any Certificate of Designation, Preferences and Rights of any outstanding series of
preferred stock of the Company or Bylaws or their organizational charter or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any term of or is in default under any material contract, agreement, mortgage,
indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or its Subsidiaries, except for possible conflicts, defaults, terminations or amendments that could not reasonably be
expected to have a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Securities Act or applicable state securities laws and the rules and regulations of the Principal Market, the Company is not
required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations
under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except as set forth elsewhere in this Agreement, all consents, authorizations, orders, filings and registrations which the Company is required to
obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Except as disclosed in the SEC Documents, since one year prior to the date hereof, the Company has not received nor delivered any notices
or correspondence from or to the Principal Market, other than notices with respect to listing of additional shares of Common Stock and other routine correspondence. Except as disclosed in the SEC Documents, the Principal Market has not commenced any
delisting proceedings against the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>SEC Documents; Financial Statements</U>. The Company has filed all
reports, schedules, forms, statements and other documents required to be filed by the Company with the SEC under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the twelve months preceding the
date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to
herein as the &#147;<U>SEC Documents</U>&#148;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension.&nbsp;As of their respective dates, the SEC
Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.&nbsp;&nbsp;&nbsp;&nbsp;None of the SEC Documents, when filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC
Documents comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing.&nbsp;Such financial statements have been prepared in accordance with
United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#147;<U>GAAP</U>&#148;), except as may be otherwise specified in such financial statements or the notes thereto and except that
unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. Except as set forth in the SEC Documents, the Company has
received no notices or correspondence from the SEC for the one year preceding the date hereof<B>.</B> The SEC has not commenced any enforcement proceedings against the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <U>Absence of Certain Changes</U>. Except as disclosed in the SEC Documents, since December&nbsp;31, 2021, there has been
no material adverse change in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries. The Company has not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to
believe that its creditors intend to initiate involuntary bankruptcy<B> </B>or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) <U>Absence of Litigation</U>. Except as disclosed in the SEC Documents, there is no action, suit, proceeding, inquiry or
investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company, the Common Stock or any
of the Company&#146;s or its Subsidiaries&#146; officers or directors in their capacities as such, which could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Acknowledgment Regarding Investor&#146;s Status</U>. The Company acknowledges and agrees that the Investor is acting
solely in the capacity of arm&#146;s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that the Investor is not acting as a financial advisor or
fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of its representatives or agents in connection with the
Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Investor&#146;s purchase of the Securities. The Company further represents to the Investor that the Company&#146;s decision to enter into the
Transaction Documents has been based solely on the independent evaluation by the Company and its representatives and advisors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) <U>No General Solicitation; No Integrated Offering</U>. Neither the Company, nor any of its affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the Securities. Neither the Company, nor or
any of its affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the offer and sale
of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to be integrated with prior offerings by the Company in a manner that would require
stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or designated. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the
Principal Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) <U>Intellectual Property Rights</U>. The Company and its Subsidiaries own or possess (or reasonably
believe it can acquire on reasonable terms) adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted. None of the Company&#146;s material trademarks, trade names, service marks, service mark registrations, service names, patents,
patent rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights have expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two
years from the date of this Agreement. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights, inventions,
licenses, service names, service marks, service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical trade secrets or technical information by others, and there is no claim, action or
proceeding being made or brought against, or to the Company&#146;s knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents, patent rights, invention, copyright,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
license, service names, service marks, service mark registrations, trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) <U>Environmental Laws</U>. Except as disclosed in the SEC Documents, the Company and its Subsidiaries (i)&nbsp;are in
compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(&#147;<U>Environmental Laws</U>&#148;), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and
conditions of any such permit, license or approval, except where, in each of the three foregoing clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m) <U>Title</U>. Neither the Company nor any of its Subsidiaries own any real property. Except as set forth in the SEC
Documents, the Company and its Subsidiaries have good and marketable title in personal property owned by them (other than intellectual property, as discussed in <U>Section</U><U></U><U>&nbsp;4(k)</U> above) that is material to the business of the
Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects (&#147;<U>Liens</U>&#148;) and, except for Liens as do not materially affect the value of such property and do not materially interfere with the use
made and proposed to be made of such property by the Company and its Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties.&nbsp;Any real property and facilities
held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and its Subsidiaries are in compliance with such exceptions as are not material and do not interfere with the
use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n) <U>Insurance</U>.
The Company and each of its Subsidiaries maintain insurance from nationally recognized, in the applicable country, insurers in such amounts and covering such risks as is commercially reasonable in accordance with customary practices for companies
engaged in similar businesses and similar industries for the conduct of their respective businesses and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries. All policies of
insurance of the Company and its Subsidiaries are in full force and effect; the Company and each of its Subsidiaries are in compliance with the terms of such policies in all material respects; and neither the Company nor any of its Subsidiaries has
received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance; there are no material claims by the Company or any of its
Subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; and neither the Company nor any such Subsidiary has any reason to believe that it will not be
able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material
Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(o) <U>Regulatory Permits</U>. Except as set forth in the SEC Documents, the Company and each of its
Subsidiaries have such permits, licenses, patents, franchises, certificates of need and other approvals consents and other authorizations (the &#147;<U>Regulatory Permits</U>&#148;) issued by the appropriate domestic or foreign regional, federal,
state, or local regulatory agencies or bodies necessary to conduct the business of the Company, including, without limitation, any Regulatory Permits required by the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;) or any other
authorizations issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of products such as those being developed by the Company and its Subsidiaries, except for any of the foregoing that would
not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect; the Company (i)&nbsp;is in compliance in all material respects with the requirements of the Regulatory Permits, and (ii)&nbsp;all of the Regulatory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Permits are valid and in full force and effect, in each case, except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse
Effect; the Company has not received any written notice of proceedings relating to the revocation, termination, modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect; the Company has not failed to submit to the FDA any applications or other filings necessary to conduct the business of the Company, any
such filings that were required to be made were in material compliance with applicable laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such filings or submissions that were made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(p) <U>Tax Status</U>. Except as disclosed in the SEC Documents, the Company and each of its Subsidiaries has made or filed all
federal and state income and all other material tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books
provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and
declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(q) <U>Transactions With Affiliates</U>. Except as set forth in the SEC Documents, none of the officers or directors of the
Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of
the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees
for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements under any stock option plan of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(r) <U>Application of Takeover Protections</U>. The Company and its board of directors have taken or will take prior to the
Commencement Date all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the
Certificate of Incorporation or the laws of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company&#146;s issuance
of the Securities and the Investor&#146;s ownership of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(s) <U>Disclosure</U>.&nbsp;Except with respect to
the material terms and conditions of the transactions contemplated by the Transaction Documents that will be timely publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided the
Investor or its agents or counsel with any information that it believes constitutes or might constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information which is not otherwise disclosed in the Registration Statement or the
SEC Documents.&nbsp;&nbsp;&nbsp;&nbsp;The Company understands and confirms that the Investor will rely on the foregoing representation in effecting purchases and sales of securities of the Company.&nbsp;All of the disclosure furnished by or on
behalf of the Company to the Investor regarding the Company, its business and the transactions contemplated hereby, including the disclosure schedules to this Agreement, is true and correct and does not contain any untrue
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading.&nbsp;The Company acknowledges and agrees that the Investor neither makes nor has made any representations or
warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;3 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(t) <U>Foreign Corrupt Practices</U>. Neither the Company nor any of its Subsidiaries, nor, to the knowledge of the Company,
any director, officer, agent, employee or other person associated with or acting on behalf of the Company or any of its Subsidiaries, has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense
relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign
Corrupt Practices Act of 1977, the Organization for <FONT STYLE="white-space:nowrap">Economic&nbsp;Co-operation&nbsp;and</FONT> Development Convention on Bribery of Foreign Public Officials in International Business Transactions, and the rules and
regulations thereunder and any other similar foreign or domestic law or regulation; or (iv)&nbsp;made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment. The Company has instituted and maintains policies and procedures
designed to ensure continued compliance with the laws and regulations referenced in clause (iii)&nbsp;of this paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(u) <U>DTC Eligibility</U>. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated
Securities Transfer (FAST) Program and the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) <U>Sarbanes-Oxley</U>. The Company is in compliance in all material respects with all provisions of the Sarbanes-Oxley Act
of 2002, as amended, which are applicable to it as of the date hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(w) <U>Certain Fees</U>. No brokerage or
finder&#146;s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction
Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this <U>Section</U><U></U><U>&nbsp;4(w)</U> that may be due in
connection with the transactions contemplated by the Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) <U>Investment Company</U>. The Company is
not, and immediately after receipt of payment for the Securities will not be, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(y) <U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC
is currently contemplating terminating such registration. Except as disclosed in the SEC Documents, the Company has not, in the twelve (12)&nbsp;months preceding the date hereof, received any notice from any Person to the effect that the Company is
not in compliance with the listing or maintenance requirements of the Principal Market. Except as disclosed in the SEC Documents, the Company is, and has no reason to believe that it will not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(z) <U>Accountants</U>. BDO USA, LLP, who have certified certain financial statements of the Company and its consolidated
Subsidiaries, whose report appears in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021, are independent public accountants as required by the Securities Act and
the Public Accounting Oversight Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(aa) <U>No Market Manipulation</U>.&nbsp;The Company has not, and to its knowledge
no Person acting on its behalf has, (i)&nbsp;taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the
Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(bb) <U>Shell Company Status</U>. The Company is not currently, and has never been, an issuer identified
in Rule 144(i)(1) under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ee) <U>Clinical Data and Regulatory Compliance</U>.&nbsp;The clinical and
preclinical studies and tests conducted by the Company and its Subsidiaries and, to the knowledge of the Company, the clinical and preclinical studies conducted on behalf of or sponsored by the Company or its Subsidiaries, were, and if still
pending, are, being conducted in all material respects in accordance with all Applicable Laws, including, but not limited to, the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and
812. Any descriptions of clinical, preclinical and other studies and tests, including any related results and regulatory status, contained in the SEC Documents are complete, accurate, and fairly represented in all material respects. Except as
disclosed in the SEC Documents and to the Company&#146;s knowledge, there are no studies, tests or trials the result of which the Company believes reasonably call into question in any material respect the clinical trial results described or referred
to in the SEC Documents when viewed in the context in which such results are described and the clinical state of development. No marketing authorization, including any 510(k) clearance held by the Company, has been terminated or suspended by the
FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the Company&#146;s knowledge, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or
ongoing clinical investigation conducted or proposed to be conducted by or on behalf of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ff) <U>Office of Foreign Assets Control</U>. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the
Company, any director, officer, agent, employee or affiliate of the Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department
(&#147;<U>OFAC</U>&#148;); and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(gg) <U>Money
Laundering</U>.&nbsp;The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act
of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any applicable related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the&nbsp;&#147;<U>Money Laundering Laws</U>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(hh) <U>No Labor Dispute</U>. No labor disturbance by or dispute with the employees of the Company or any of its Subsidiaries
exists or, to the knowledge of the Company, is imminent that could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(jj) <U>No Immunity</U>. Neither the Company nor any Subsidiary, nor any of their respective properties or assets, has any
immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment to prior judgment, attachment in aid of execution or otherwise) under the laws of any jurisdiction in which it is organized,
headquartered or doing business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(kk) <U>Information Technology</U>. The Company&#146;s and the Subsidiaries&#146;
information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<U>IT Systems</U>&#148;) operate and perform in all material respects as required in connection
with the operation of the business of the Company and the Subsidiaries as currently conducted. The Company, and the Subsidiaries maintain commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and all personal, personally identifiable, sensitive, confidential or regulated data (&#147;<U>Personal Data</U>&#148;) processed and stored
thereon, and to the knowledge of the Company, there have been no breaches, incidents, violations, outages, compromises or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the
duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and the Subsidiaries are presently in compliance in all material respects with all applicable laws or statutes and all
applicable judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the
protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification, except for any such noncompliance that would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ll) <U>No Disqualification Events</U>. None of the Company, any of its predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company&#146;s outstanding voting equity securities, calculated on the basis of voting power, nor any
promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &#147;<U>Issuer Covered Person</U>&#148;) is subject to any of the &#147;Bad Actor&#148;
disqualifications described in Rule 506(d)(1)(i) to (viii)&nbsp;under the Securities Act (a &#147;<U>Disqualification Event</U>&#148;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has
exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>COVENANTS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Filing of Current Report and Registration Statement</U>. The Company agrees that it shall, within the time required
under the Exchange Act, file with the SEC a report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> relating to the transactions contemplated by, and describing the material terms and conditions of, the Transaction Documents (the &#147;<U>Current
Report</U>&#148;). The Company shall also file with the SEC, within thirty (30)&nbsp;Business Days from the date hereof, a new registration statement (the &#147;<U>Registration Statement</U>&#148;) covering only the resale of the Purchase Shares and
all of the Initial Commitment Shares and Additional Commitment Shares, in accordance with the terms of the Registration Rights Agreement between the Company and the Investor, dated as of the date hereof (the &#147;<U>Registration Rights
Agreement</U>&#148;). The Company shall permit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Investor to review and comment upon the final <FONT STYLE="white-space:nowrap">pre-filing</FONT> draft version of the Current Report at least two (2)&nbsp;Business Days prior to its filing
with the SEC, and the Company shall give due consideration to all such comments. The Investor shall use its reasonable best efforts to comment upon the final <FONT STYLE="white-space:nowrap">pre-filing</FONT> draft version of the Current Report
within one (1)&nbsp;Business Day from the date the Investor receives it from the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Blue Sky</U>. The Company
shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to register or qualify (i)&nbsp;the issuance of the Commitment Shares and the sale of the Purchase Shares to the Investor under this Agreement and
(ii)&nbsp;any subsequent resale of all Commitment Shares and all Purchase Shares by the Investor, in each case, under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States in such states as is reasonably requested by
the Investor from time to time, and shall provide evidence of any such action so taken to the Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)
<U>Listing/DTC</U>. The Company shall promptly secure the listing of all of the Purchase Shares and Commitment Shares to be issued to the Investor hereunder on the Principal Market (subject to official notice of issuance) and upon each other
national securities exchange or automated quotation system, if any, upon which the Common Stock is then listed, and shall use commercially reasonable efforts to maintain, so long as any shares of Common Stock shall be so listed, such listing of all
such Securities from time to time issuable hereunder. The Company shall use commercially reasonable efforts to maintain the listing of the Common Stock on the Principal Market and shall comply in all respects with the Company&#146;s reporting,
filing and other obligations under the bylaws or rules and regulations of the Principal Market. Neither the Company nor any of its Subsidiaries shall take any action that would reasonably be expected to result in the delisting or suspension of the
Common Stock on the Principal Market. The Company shall promptly, and in no event later than the following Business Day, provide to the Investor copies of any notices it receives from any Person regarding the continued eligibility of the Common
Stock for listing on the Principal Market; provided, however, that the Company shall not be required to provide the Investor copies of any such notice that the Company reasonably believes constitutes material
<FONT STYLE="white-space:nowrap">non-public</FONT> information and the Company would not be required to publicly disclose such notice in any report or statement filed with the SEC and under the Exchange Act or the Securities Act. The Company shall
pay all fees and expenses in connection with satisfying its obligations under this <U>Section</U><U></U><U>&nbsp;5(c)</U>. The Company shall take all action necessary to ensure that its Common Stock can be transferred electronically as DWAC Shares.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Prohibition of Short Sales and Hedging Transactions</U>. The Investor agrees that beginning on the date of this
Agreement and ending on the date of termination of this Agreement as provided in Section&nbsp;11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i)
&#147;short sale&#148; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii)&nbsp;hedging transaction, which establishes a net short position with respect to the Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Payment of Commitment Fee/Issuance of Commitment Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Initial Commitment Fee/Initial Commitment Shares</U>. In consideration for the Investor&#146;s execution
and delivery of this Agreement, the Company shall (X)&nbsp;pay to the Investor, by wire transfer of immediately available funds to an account designated by the Investor, an amount in cash equal to $125,000 (the &#147;<U>Initial Commitment
Fee</U>&#148;) immediately upon the execution of this Agreement, and (Y)&nbsp;cause to be issued to the Investor a total of 492,698 shares of Common Stock (the &#147;<U>Initial Commitment Shares</U>&#148;) immediately upon the execution of this
Agreement and shall deliver to the Transfer Agent the Irrevocable Transfer Agent Instructions with respect to the issuance of such Initial Commitment Shares. For the avoidance of doubt, the entire Initial Commitment
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Fee and all of the Initial Commitment Shares shall be fully earned by the Investor as of the date of this Agreement, whether or not the Commencement shall occur or any Purchase Shares are
purchased by the Investor under this Agreement and irrespective of any subsequent termination of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Additional Commitment Shares</U>. Not later than 4:00 p.m. (New York City time) on the trading day on
which the Company shall have received from the Investor total aggregate cash proceeds equal to $25,000,000 as payment for all shares purchased by the Investor in all Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases
effected pursuant to this Agreement (the &#147;<U>Additional Fee Trigger Date</U>&#148;), the Company shall pay to the Investor an amount in cash, stock or a combination of cash of stock that together is equal to $625,000 (the &#147;<U>Additional
Commitment Fee</U>&#148; and any stock issued as part of the Additional Commitment Fee, the &#147;<U>Additional Commitment Shares</U>&#148;). If Additional Commitment Shares are issued, such shares (i)&nbsp;shall have a per share value equal to the
Purchase Price and (ii)&nbsp;shall be received by the Investor as DWAC Shares not later than 10:00 a.m. (New York City time) on the next trading day. For the avoidance of doubt, the entire Additional Commitment Fee (including any Additional
Commitment Shares), shall be fully earned by the Investor as of the Additional Fee Trigger Date, whether or not any additional Purchase Shares are purchased thereafter by the Investor under this Agreement and irrespective of any subsequent
termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>Due Diligence; <FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</U>.
During the term of this Agreement, the Investor shall have the right, from time to time as the Investor may reasonably deem appropriate and upon reasonable advance notice to the Company, to perform reasonable due diligence on the Company during
normal business hours. The Company and its officers and employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the Investor related to the Investor&#146;s due diligence of the
Company. Each party hereto agrees not to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions
contemplated hereby in full compliance with applicable securities laws. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to
protect the secrecy of any Confidential Information disclosed by the other party. The receiving party may disclose Confidential Information to the extent such information is required to be disclosed by law, regulation or order of a court of
competent jurisdiction or regulatory authority, provided that the receiving party shall promptly notify the disclosing party when such requirement to disclose arises, and shall cooperate with the disclosing party so as to enable the disclosing party
to: (i)&nbsp;seek an appropriate protective order; and (ii)&nbsp;make any applicable claim of confidentiality in respect of such Confidential Information; and provided, further, that the receiving party shall disclose Confidential Information only
to the extent required by the protective order or other similar order, if such an order is obtained, and, if no such order is obtained, the receiving party shall disclose only the minimum amount of such Confidential Information required to be
disclosed in order to comply with the applicable law, regulation or order. In addition, any such Confidential Information disclosed pursuant to this section shall continue to be deemed Confidential Information. Notwithstanding anything in this
Agreement to the contrary, the Company and the Investor agree that neither the Company nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes or might reasonably be
considered to constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the
foregoing covenant by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents, if the Investor is
holding any Securities at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
time of the disclosure of such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Investor shall have the right to make a public disclosure, in the form of a press
release, public advertisement or otherwise, of such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it
believes it has received information that constitutes material, <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall have at least 24 hours to either publicly disclose such material,
<FONT STYLE="white-space:nowrap">non-public</FONT> information prior to any such disclosure by the Investor or to demonstrate to the Investor that such information does not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information prior to any such disclosure by the Investor, and the Company shall have failed to publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information or to demonstrate to the Investor that such information
does not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information within such time period. The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers,
employees, stockholders or agents, for any such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <U>Purchase Records</U>. The Investor and the Company shall each maintain records showing the remaining Available Amount at
any given time and the dates and Purchase Amounts for each Regular Purchase, Accelerated Purchase and Additional Accelerated Purchase or shall use such other method, reasonably satisfactory to the Investor and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) <U>Taxes.</U> The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the
issuance and delivery of any shares of Common Stock to the Investor made under this Agreement.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Use of
Proceeds</U>. The Company will use the net proceeds from the offering as described in the Registration Statement or the SEC Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) <U>Other Transactions</U>. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan,
arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the
obligation of the Company to deliver the Purchase Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents, for so long as such obligations of the Company are in effect pursuant to the terms of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) <U>Integration</U>. From and after the date of this Agreement, neither the Company, nor or any of its
affiliates will, and the Company shall use its reasonable best efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any security, under
circumstances that would (i)&nbsp;require registration of the offer and sale by the Company to the Investor of any of the Securities under the Securities Act, or (ii)&nbsp;cause this offering of the Securities by the Company to the Investor to be
integrated with other offerings by the Company in a manner that would require stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or designated, unless in the case of this
clause (ii), stockholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of such Principal Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) <U>Limitation on Variable Rate Transactions.</U> From and after the date of this Agreement until the later of: (i)&nbsp;the
<FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date of this Agreement and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the Commencement Date (if the Commencement has occurred), in either case
irrespective of any earlier termination of this Agreement, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or
a combination of units thereof) involving a Variable Rate Transaction, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
other than in connection with an Exempt Issuance (as defined below).. The Investor shall be entitled to seek injunctive relief against the Company and its Subsidiaries to preclude any such
issuance, which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required. &#147;<U>Common Stock Equivalents</U>&#148; means any securities of
the Company or its Subsidiaries which entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or
exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. &#147;<U>Variable Rate Transaction</U>&#148; means a transaction in which the Company (i)&nbsp;issues or sells any equity or debt securities that are
convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock or Common Stock Equivalents either (A)&nbsp;at a conversion price, exercise price, exchange rate or other price that is based upon
and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such equity or debt securities, or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such equity or debt security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (including, without
limitation, any &#147;full ratchet&#148; or &#147;weighted average&#148; anti-dilution provisions, but not including any standard anti-dilution protection for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT>
dividend, stock split or other similar transaction), (ii) issues or sells any equity or debt securities, including without limitation, Common Stock or Common Stock Equivalents, either (A)&nbsp;at a price that is subject to being reset at some future
date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (other than standard
anti-dilution protection for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction), or (B)&nbsp;that is subject to or contains any put, call, redemption, <FONT
STYLE="white-space:nowrap">buy-back,</FONT> price-reset or other similar provision or mechanism (including, without limitation, a &#147;Black-Scholes&#148; put or call right, other than in connection with a &#147;fundamental transaction&#148;) that
provides for the issuance of additional equity securities of the Company or the payment of cash by the Company, or (iii)&nbsp;enters into any agreement, including, but not limited to, an &#147;equity line of credit&#148; or other continuous offering
or similar offering of Common Stock or Common Stock Equivalents, whereby the Company may sell Common Stock or Common Stock Equivalents at a future determined price. For the avoidance of doubt, the offering and sale by the Company of Common Stock
Equivalents with a customary anti-dilution adjustment that is triggered by the Company&#146;s subsequent sale of equity securities at a price lower than the applicable conversion price shall not be deemed to be a prohibited Variable Rate
Transaction. &#147;<U>Exempt Issuance</U>&#148; means the issuance of (a)&nbsp;Common Stock, options or other equity incentive awards to employees, officers, directors or vendors of the Company pursuant to any equity incentive plan or stock purchase
plan duly adopted for such purpose, by the Board of Directors of the Company or a majority of the members of a committee of directors established for such purpose, (b)&nbsp;(1) any Securities issued to the Investor pursuant to this Agreement,
(2)&nbsp;any securities issued upon the exercise or exchange of or conversion of any shares of Common Stock or Common Stock Equivalents held by the Investor at any time, (3)&nbsp;shares of Common Stock, Common Stock Equivalents or other securities
issued to the Investor pursuant to any other existing or future contract, agreement or arrangement between the Company and the Investor, or (4)&nbsp;any securities issued upon the exercise or exchange of or conversion of any Common Stock Equivalents
issued and outstanding on the date of this Agreement, provided that such securities referred to in this clause (3)&nbsp;have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities, (c)&nbsp;securities issued pursuant to acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions approved by the Board of Directors or a majority of the
members of a committee of directors established for such purpose, which acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions can have a Variable Rate Transaction component, (d)&nbsp;Common Stock issued
pursuant to an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market</FONT></FONT> offering&#148; by the Company exclusively through a registered broker-dealer acting as agent of the Company pursuant to a written
agreement between the Company and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
such registered broker-dealer, (e)&nbsp;debt or preferred securities, including, without limitation, debt or preferred securities that are convertible into or exchangeable for, or include the
right to receive, shares of Common Stock, issued to a strategic party in a transaction in which the Company is not issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities,
either (A)&nbsp;at a fixed price, (B)&nbsp;at a price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such debt or preferred securities, or (C)&nbsp;at a price
that is subject to being reset at some future date after the initial issuance of such debt security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common
Stock, or (f)&nbsp;warrants or options or other Common Stock Equivalents that are convertible into, exchangeable or exercisable for, or include the right to receive, shares of Common Stock at a fixed price (which may be below the then current market
price of the Common Stock), subject only to standard anti-dilution protection for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split or other similar transaction. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>TRANSFER AGENT INSTRUCTIONS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)<B> </B>On the date of this Agreement, the Company shall issue irrevocable instructions to the Transfer Agent substantially
in the form attached hereto as <B><U>Exhibit C</U></B> to issue the Initial Commitment Shares in accordance with the terms of this Agreement (the &#147;<U>Irrevocable Transfer Agent Instructions</U>&#148;). The certificate(s) or book-entry
statement(s) representing the Initial Commitment Shares, except as set forth below, shall bear the following restrictive legend (the &#147;<U>Restrictive Legend</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1)&nbsp;RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2)&nbsp;AN OPINION OF HOLDER&#146;S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED
UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) On the earlier of (i)&nbsp;the Commencement Date and
(ii)&nbsp;such time that the Investor shall request, provided all conditions of Rule 144 under the Securities Act are met, the Company shall, no later than one (1)&nbsp;Business Day following the delivery by the Investor to the Company or the
Transfer Agent of one or more legended certificates or book-entry statements representing the Initial Commitment Shares (which certificates or book-entry statements the Investor shall promptly deliver on or prior to the first to occur of the events
described in clauses (i)&nbsp;and (ii) of this sentence), as directed by the Investor, issue and deliver (or cause to be issued and delivered) to the Investor, as requested by the Investor, either: (A)&nbsp;a certificate or book-entry statement
representing such Initial Commitment Shares that is free from all restrictive and other legends or (B)&nbsp;a number of shares of Common Stock equal to the number of Initial Commitment Shares represented by the certificate(s) or book-entry
statement(s) so delivered by the Investor as DWAC Shares. The Company shall take all actions to carry out the intent and accomplish the purposes of the immediately preceding sentence, including, without limitation, delivering all such legal
opinions, consents, certificates, resolutions and instructions to the Transfer Agent, and any successor transfer agent of the Company, as may be requested from time to time by the Investor or necessary or desirable to carry out the intent and
accomplish the purposes of the immediately preceding sentence. On the Commencement Date, the Company shall issue to the Transfer Agent, and any subsequent transfer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
agent, (i)&nbsp;irrevocable instructions in the form substantially similar to those used by the Investor in substantially similar transactions (the &#147;<U>Commencement Irrevocable Transfer
Agent Instructions</U>&#148;) and (ii)&nbsp;the notice of effectiveness of the Registration Statement in the form attached as an exhibit to the Registration Rights Agreement (the &#147;<U>Notice of Effectiveness of Registration Statement</U>&#148;),
in each case to issue the Commitment Shares and the Purchase Shares in accordance with the terms of this Agreement and the Registration Rights Agreement. All Purchase Shares and Additional Commitment Shares to be issued from and after Commencement
to or for the benefit of the Investor pursuant to this Agreement shall be issued only as DWAC Shares. The Company represents and warrants to the Investor that, while this Agreement is effective, no instruction other than the Commencement Irrevocable
Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement referred to in this <U>Section</U><U></U><U>&nbsp;6(b)</U> will be given by the Company to the Transfer Agent with respect to the Purchase Shares or the Commitment
Shares from and after Commencement, and the Purchase Shares and the Commitment Shares covered by the Registration Statement shall otherwise be freely transferable on the books and records of the Company. If the Investor effects a sale, assignment or
transfer of the Purchase Shares, the Company shall permit the transfer and shall promptly instruct the Transfer Agent (and any subsequent transfer agent) to issue DWAC Shares in such name and in such denominations as specified by the Investor to
effect such sale, transfer or assignment. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investor. Accordingly, the Company acknowledges that the remedy at law for a breach of its
obligations under this <U>Section</U><U></U><U>&nbsp;6 </U>will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this <U>Section</U><U></U><U>&nbsp;6</U>, that the Investor shall be
entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security being
required. The Company agrees that if the Company fails to fully comply with the provisions of this <U>Section</U><U></U><U>&nbsp;6(b)</U> within five (5)&nbsp;Business Days of the Investor providing the deliveries referred to above, the Company
shall, at the Investor&#146;s written instruction, purchase such shares of Common Stock containing the restrictive legend from the Investor at the greater of the (i)&nbsp;purchase price paid for such shares of Common Stock (as applicable) and
(ii)&nbsp;the Closing Sale Price of the Common Stock on the date of the Investor&#146;s written instruction. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>CONDITIONS TO THE COMPANY&#146;S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The right of the Company hereunder to commence sales of the Purchase Shares on the Commencement
Date is subject to the satisfaction of each of the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;The Investor shall have executed each of
the Transaction Documents and delivered the same to the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;The Registration Statement covering the resale
of the Purchase Shares and all of the Commitment Shares shall have been declared effective under the Securities Act by the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC; and</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;The representations and warranties of the Investor shall be true and correct in all material respects as of the date
hereof and as of the Commencement Date as though made at that time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>CONDITIONS TO THE INVESTOR&#146;S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The obligation of the Investor to buy Purchase Shares under this Agreement is subject to the
satisfaction of each of the following conditions on or prior to the Commencement Date and, once such conditions have been initially satisfied, there shall not be any ongoing obligation to satisfy such conditions after the Commencement has occurred:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Company shall have executed each of the Transaction Documents and delivered the same to the Investor; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The Company shall have issued or caused to be issued to the Investor (i)&nbsp;one or more certificates or book-entry statements
representing the Initial Commitment Shares free from all restrictive and other legends or (ii)&nbsp;a number of shares of Common Stock equal to the number of Initial Commitment Shares as DWAC Shares, in each case in accordance with
<U>Section</U><U></U><U>&nbsp;6(b)</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The Common Stock shall be listed or quoted on the Principal Market, trading in
the Common Stock shall not have been within the last 365 days suspended by the SEC or the Principal Market, and all Securities to be issued by the Company to the Investor pursuant to this Agreement shall have been approved for listing or quotation
on the Principal Market in accordance with the applicable rules and regulations of the Principal Market, subject only to official notice of issuance; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The Investor shall have received the opinions and negative assurances of the Company&#146;s legal counsel dated as of the
Commencement Date substantially in the forms heretofore agreed by the parties hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) The representations and
warranties of the Company shall be true and correct in all material respects (except to the extent that any of such representations and warranties is already qualified as to materiality in Section&nbsp;4 above, in which case, the portion of such
representations and warranties so qualified shall be true and correct without further qualification) as of the date hereof and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a
specific date, which shall be true and correct as of such date) and the Company shall have performed, satisfied and complied with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied
with by the Company at or prior to the Commencement Date. The Investor shall have received a certificate, executed by the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect substantially in the form
attached hereto as <B><U>Exhibit A</U></B>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) The Board of Directors of the Company shall have adopted the Signing
Resolutions, which shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) As of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common Stock
(i)&nbsp;solely for the purpose of effecting purchases of Purchase Shares hereunder, 14,036,665 shares of Common Stock, and (ii)&nbsp;solely for purposes of issuing the Additional Commitment Shares, 985,396 shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) The Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement each
shall have been delivered to and acknowledged in writing by the Company and the Company&#146;s Transfer Agent (or any successor transfer agent); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) The Company shall have delivered to the Investor a certificate
evidencing the incorporation and good standing of the Company in the State of Delaware issued by the Secretary of State of the State of Delaware as of a date within ten (10)&nbsp;Business Days of the Commencement Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) The Company shall have delivered to the Investor a certified copy of the Certificate of Incorporation as certified by the
Secretary of State of the State of Delaware within ten (10)&nbsp;Business Days of the Commencement Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) The Company
shall have delivered to the Investor a secretary&#146;s certificate executed by the Secretary of the Company, dated as of the Commencement Date, in the form attached hereto as <B><U>Exhibit B</U></B>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) The Registration Statement covering the resale of the Purchase Shares and all of the Commitment Shares shall have been
declared effective under the Securities Act by the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC. The Company shall have prepared and filed with the SEC, not later than one
(1)&nbsp;Business Day after the effective date of the Registration Statement, a final and complete prospectus (the preliminary form of which shall be included in the Registration Statement) and shall have delivered to the Investor a true and
complete copy thereof. Such prospectus shall be current and available for the resale by the Investor of all of the Securities covered thereby. The Current Report shall have been filed with the SEC, as required pursuant to
<U>Section</U><U></U><U>&nbsp;5(a)</U>. All reports, schedules, registrations, forms, statements, information and other documents required to have been filed by the Company with the SEC at or prior to the Commencement Date pursuant to the reporting
requirements of the Exchange Act shall have been filed with the SEC within the applicable time periods prescribed for such filings under the Exchange Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m) No Event of Default has occurred, or any event which, after notice and/or lapse of time, would become an Event of Default
has occurred; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n) All federal, state and local governmental laws, rules and regulations applicable to the transactions
contemplated by the Transaction Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been
complied with, and all consents, authorizations and orders of, and all filings and registrations with, all federal, state and local courts or governmental agencies and all federal, state and local regulatory or self-regulatory agencies necessary for
the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or made, including, without limitation, in each case
those required under the Securities Act, the Exchange Act, applicable state securities or &#147;Blue Sky&#148; laws or applicable rules and regulations of the Principal Market, or otherwise required by the SEC, the Principal Market or any state
securities regulators; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(o) No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted,
entered, promulgated, threatened or endorsed by any federal, state, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any of the transactions
contemplated by the Transaction Documents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(p) No action, suit or proceeding before any federal, state, local or foreign
arbitrator or any court or governmental authority of competent jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign governmental authority of competent jurisdiction shall have
been commenced or threatened, against the Company, or any of the officers, directors or affiliates of the Company, seeking to restrain, prevent or change the transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
contemplated by the Transaction Documents, or seeking material damages in connection with such transactions; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(q) The Stockholders&#146; Approval shall be in full force and effect without any amendment or supplement thereto as of the
date of this Agreement, and the Company shall have delivered to the Investor a true, correct and complete copy of the report of the inspector of elections of the 2022 Annual Meeting of Stockholders of the Company at which the Stockholders&#146;
Approval was obtained. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>INDEMNIFICATION. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In consideration of the Investor&#146;s execution and delivery of the Transaction Documents and acquiring the Securities
hereunder and in addition to all of the Company&#146;s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Investor and all of its affiliates, stockholders, members, officers,
directors, employees and direct or indirect investors and any of the foregoing Person&#146;s agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement)
(collectively, the &#147;<U>Indemnitees</U>&#148;) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such
Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys&#146; fees and disbursements (the &#147;<U>Indemnified Liabilities</U>&#148;), incurred by any Indemnitee as a result of, or
arising out of, or relating to (a)&nbsp;any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b)&nbsp;any
breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, or (c)&nbsp;any cause of action, suit or claim brought or made
against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, other than, in the case of
clause (c), with respect to Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful misconduct of an Indemnitee. The indemnity in this Section&nbsp;9 shall not apply to amounts paid in settlement of
any claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for
any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. Payment under this indemnification shall be made within thirty
(30)&nbsp;days from the date Investor makes written request for it. A certificate containing reasonable detail as to the amount of such indemnification submitted to the Company by Investor shall be conclusive evidence, absent manifest error, of the
amount due from the Company to to the Investor; provided that the Investor shall undertake to repay any amount paid to it hereunder if it is ultimately determined, by a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> order of a
court of competent jurisdiction, that the Investor is not entitled to be indemnified against such Indemnified Liability by the Company pursuant to this Agreement. If any action shall be brought against any Indemnitee in respect of which indemnity
may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any
Indemnitee shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnitee, except to the extent that (i)&nbsp;the
employment thereof has been specifically authorized by the Company in writing, (ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)&nbsp;in such action there is, in the reasonable
opinion of such separate counsel, a material conflict on any material issue between the position of the Company and the position of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>EVENTS OF DEFAULT. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An &#147;<U>Event of Default</U>&#148; shall be deemed to have occurred at any time as any of the following events occurs: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) the effectiveness of a registration statement registering the resale of the Securities lapses for any reason (including,
without limitation, the issuance of a stop order or similar order) or such registration statement (or the prospectus forming a part thereof) is unavailable to the Investor for resale of any or all of the Securities to be issued to the Investor under
the Transaction Documents, and such lapse or unavailability continues for a period of ten (10)&nbsp;consecutive Business Days or for more than an aggregate of thirty (30)&nbsp;Business Days in any <FONT STYLE="white-space:nowrap">365-day</FONT>
period, but excluding a lapse or unavailability where (i)&nbsp;the Company terminates a registration statement after the Investor has confirmed in writing that all of the Securities covered thereby have been resold or (ii)&nbsp;the Company
supersedes one registration statement with another registration statement, including (without limitation) by terminating a prior registration statement when it is effectively replaced with a new registration statement covering Securities (provided
in the case of this clause (ii)&nbsp;that all of the Securities covered by the superseded (or terminated) registration statement that have not theretofore been resold are included in the superseding (or new) registration statement); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) the suspension of the Common Stock from trading on the Principal Market for a period of one (1)&nbsp;Business Day, provided
that the Company may not direct the Investor to purchase any shares of Common Stock during any such suspension; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) the
delisting of the Common Stock from The Nasdaq Capital Market (or any nationally recognized successor thereto), provided, however, that the Common Stock is not immediately thereafter trading on the New York Stock Exchange, The Nasdaq Global Market,
The Nasdaq Global Select Market, the NYSE American, the NYSE Arca, the OTC Bulletin Board, or the OTCQX or OTCQB operated by OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) the failure for any reason by the Transfer Agent to issue (i)&nbsp;the Additional Commitment Shares to the Investor within
two (2)&nbsp;Business Days after the date on which the Investor is entitled to receive such Additional Commitment Shares pursuant to <U>Section</U><U></U><U>&nbsp;5(e)</U> hereof or (ii)&nbsp;Purchase Shares to the Investor within two
(2)&nbsp;Business Days after the Purchase Date, Accelerated Purchase Date or Additional Accelerated Purchase Date, as applicable, on which the Investor is entitled to receive such Purchase Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) the Company breaches any representation, warranty, covenant or other term or condition under any Transaction Document if
such breach would reasonably be expected to have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if such breach continues for a period of at least five (5)&nbsp;Business Days; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) if any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) if the Company, pursuant to or within the meaning of any Bankruptcy Law, (i)&nbsp;commences a voluntary case,
(ii)&nbsp;consents to the entry of an order for relief against it in an involuntary case, (iii)&nbsp;consents to the appointment of a Custodian of it or for all or substantially all of its property, or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(iv) makes a general assignment for the benefit of its creditors or is generally unable to pay its debts as the same become due; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i)&nbsp;is for relief against
the Company in an involuntary case, (ii)&nbsp;appoints a Custodian of the Company or for all or substantially all of its property, or (iii)&nbsp;orders the liquidation of the Company or any Subsidiary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) if at any time the Company is not eligible to transfer its Common Stock electronically as DWAC Shares; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) if at any time after the Commencement Date, the Maximum Share Cap is reached, and the stockholder approval referred to in
<U>Section</U><U></U><U>&nbsp;2(e)(i)</U> has not been obtained in accordance with the applicable rules of The Nasdaq Stock Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition to any other rights and remedies under applicable law and this Agreement, so long as an Event of Default has occurred and is continuing, or if any event which, after notice and/or lapse of time, would reasonably be expected to become an
Event of Default, has occurred and is continuing, the Company shall not deliver to the Investor any Regular Purchase Notice, Accelerated Purchase Notice or Additional Accelerated Purchase Notice. Notwithstanding the foregoing, the foregoing sentence
shall not be deemed to apply to any notice from Nasdaq received in the future regarding the Company&#146;s failure to comply with the continuing listing standards of The Nasdaq Capital Market, and to the fact of each such failure, unless all
compliance and appeal periods for such failure have lapsed or expired; provided, however, that this sentence shall not be construed to modify any of the Events of Default enumerated above in this Section&nbsp;10. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Agreement may be terminated only as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) If pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences
a proceeding against the Company which is not discharged within 90 days, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors (any of
which would be an Event of Default as described in <U>Sections 10(f)</U>, <U>10(g)</U> and <U>10(h)</U> hereof), this Agreement shall automatically terminate without any liability or payment to the Company (except as set forth below) without further
action or notice by any Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) In the event that (i)&nbsp;the Company fails to file the Registration Statement with
the SEC within the period specified in <U>Section</U><U></U><U>&nbsp;5(a)</U> hereof in accordance with the terms of the Registration Rights Agreement or (ii)&nbsp;the Commencement shall not have occurred on or before August&nbsp;31, 2022, due to
the failure to satisfy the conditions set forth in <U>Sections 7</U> and <U>8</U> above with respect to the Commencement, then, in the case of clause (i)&nbsp;above, this Agreement may be terminated by the Investor at any time prior to the filing of
the Registration Statement and, in the case of clause (ii)&nbsp;above, this Agreement may be terminated by either party at the close of business on August&nbsp;31, 2022 or thereafter, in each case without liability of such party to the other party
(except as set forth below); provided, however, that the right to terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;11(b)</U> shall not be available to any party if such party is then in breach of any covenant or agreement contained
in this Agreement or any representation or warranty of such party contained in this Agreement fails to be true and correct such that the conditions set forth in <U>Section</U><U></U><U>&nbsp;7(c)</U> or <U>Section</U><U></U><U>&nbsp;8(e)</U>, as
applicable, could not then be satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) At any time after the Commencement Date, the Company shall have the
option to terminate this Agreement for any reason or for no reason by delivering notice (a &#147;<U>Company Termination Notice</U>&#148;) to the Investor electing to terminate this Agreement without any liability whatsoever of any party to any other
party under this Agreement (except as set forth below). The Company Termination Notice shall not be effective until one (1)&nbsp;Business Day after it has been received by the Investor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) This Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full
Available Amount as provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) If, for any reason or for no reason, the full Available Amount has not been purchased in accordance with
<U>Section</U><U></U><U>&nbsp;2</U> of this Agreement by the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the part of any party and without any liability whatsoever of any party to
any other party under this Agreement (except as set forth below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as set forth in <U>Sections 11(a)</U> (in respect of an Event of
Default under <U>Sections 10(f)</U>, <U>10(g)</U> and 10(h)), <U>11(d)</U> and <U>11(e)</U>, any termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;11</U> shall be effected by written notice from the Company to the
Investor, or the Investor to the Company, as the case may be, setting forth the basis for the termination hereof. The representations and warranties and covenants of the Company and the Investor contained in <U>Sections 3</U>, <U>4</U>, <U>5</U>,
and <U>6</U> hereof, the indemnification provisions set forth in <U>Section</U><U></U><U>&nbsp;9</U> hereof and the agreements and covenants set forth in <U>Sections</U><B><U> </U></B><U>10</U>, <U>11</U> and <U>12</U> shall survive the execution
and delivery of this Agreement and any termination of this Agreement. No termination of this Agreement shall (i)&nbsp;affect the Company&#146;s or the Investor&#146;s rights or obligations under (A)&nbsp;this Agreement with respect to pending
Regular Purchases, Accelerated Purchases or Additional Accelerated Purchases and the Company and the Investor shall complete their respective obligations with respect to any pending Regular Purchases, Accelerated Purchases and Additional Accelerated
Purchases under this Agreement and (B)&nbsp;the Registration Rights Agreement, which shall survive any such termination, or (ii)&nbsp;be deemed to release the Company or the Investor from any liability for intentional misrepresentation or willful
breach of any of the Transaction Documents. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>MISCELLANEOUS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;(a) <U>Governing Law; Jurisdiction; Jury Trial</U>. The corporate laws of the State of Delaware shall govern all
issues concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this Agreement, the Registration Rights Agreement and the other Transaction
Documents shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of and venue in the U.S. District Court for the Southern District of New York or, if that court does not have
subject matter jurisdiction, in any state court located in the city and county of New York, for the adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
process in any manner permitted by law. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Counterparts</U>.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided
that a facsimile signature or signature delivered by <FONT STYLE="white-space:nowrap">e-mail</FONT> in a &#147;.pdf&#148; format data file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com,
www.echosign.adobe.com, etc., shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Headings</U>. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Severability</U>. If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in
any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Entire Agreement</U>. The Transaction Documents supersede all other prior oral or written
agreements between the Investor, the Company, their affiliates and Persons acting on their behalf with respect to the subject matter thereof, and this Agreement, the other Transaction Documents and the instruments referenced herein contain the
entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with
respect to such matters. The Company acknowledges and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>Notices</U>. Any notices, consents, waivers or other communications required or permitted to be given under the terms of
this Agreement must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt when delivered personally; (ii)&nbsp;upon receipt when sent by facsimile or email (provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party); or (iii)&nbsp;one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses
and facsimile numbers and email addresses for such communications shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plus Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4200 Marathon Blvd., Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Austin, Texas 78756 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Telephone: &nbsp;&nbsp;&nbsp;&nbsp;(737) <FONT STYLE="white-space:nowrap">255-7194</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;asims@plustherapeutics.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Andrew Sims&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hogan Lovells US LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">609 Main Street, Suite 4200 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Houston, TX 77002 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Telephone: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(713) <FONT STYLE="white-space:nowrap">632-1400</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Facsimile: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(713) <FONT STYLE="white-space:nowrap">632-1401</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;andrew.strong@hoganlovells.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;william.intner@hoganlovells.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Andrew L. Strong </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;William I. Intner </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to the Investor: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lincoln Park Capital Fund, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">440 North Wells, Suite 410 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chicago, IL 60654 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Telephone:&nbsp;&nbsp;&nbsp;&nbsp; (312) <FONT STYLE="white-space:nowrap">822-9300</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (312) <FONT STYLE="white-space:nowrap">822-9301</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
jscheinfeld@lpcfunds.com/jcope@lpcfunds.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Josh
Scheinfeld/Jonathan Cope </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dorsey&nbsp;&amp; Whitney LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">51 West 52<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, NY 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Telephone:&nbsp;&nbsp;&nbsp;&nbsp; (212) <FONT STYLE="white-space:nowrap">415-9214</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Facsimile: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(212) <FONT STYLE="white-space:nowrap">953-7201</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;marsico.anthony@dorsey.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anthony J. Marsico </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to the Transfer Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Computershare Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">250 Royall Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Canton, MA 02021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Telephone: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(303) <FONT STYLE="white-space:nowrap">262-0616</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Facsimile: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(303) <FONT STYLE="white-space:nowrap">262-0610</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consuelo Galicia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;Relationship Manager </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">or at such other address, email address and/or facsimile number and/or to the attention of such other Person as the recipient party has
specified by written notice given to each other party three (3)&nbsp;Business Days prior to the effectiveness of such change. Written confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent or other communication,
(B)&nbsp;mechanically or electronically generated by the sender&#146;s facsimile machine or email account containing the time, date, and recipient facsimile number or email address, as applicable, and an image of the first page of such transmission
or (C)&nbsp;provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii)
or (iii)&nbsp;above, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to
the benefit of the parties and their respective successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor; provided, however, that any transaction,
whether by merger, reorganization, restructuring, or consolidation, financing or otherwise, whereby the Company remains the surviving entity immediately after such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
transaction shall not be deemed an assignment. The Investor may not assign its rights or obligations under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) <U>No Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns and, except as set forth in Section&nbsp;9, is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Publicity</U>. The Company shall afford the Investor and its counsel with the opportunity to review and comment upon,
shall consult with the Investor and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release, SEC filing or any other public disclosure by or on behalf of
the Company relating to the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior to the issuance, filing or public disclosure thereof; provided, however,
that this provision shall not apply to any portion of any Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q</FONT> that does not relate to the Investor, its purchases hereunder or any aspect of the
Transaction Documents or the transactions contemplated hereby. The Investor must be provided with a final version of any portion of such press release, SEC filing or other public disclosure relating to the Investor, its purchases hereunder or any
aspect of the Transaction Documents or the transactions contemplated hereby at least 24 hours prior to any release, filing or use by the Company thereof. The Company agrees and acknowledges that its failure to fully comply with this provision
constitutes a Material Adverse Effect. The Investor shall not make any public announcement or disclosure regarding this Agreement and the transactions contemplated hereby without the prior written consent of the Company, except as may be required by
applicable law or pursuant to the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) <U>Further Assurances</U>. Each party shall do and perform,
or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to consummate and make
effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) <U>No Financial Advisor, Placement Agent, Broker or Finder</U>. The Company represents and warrants to the Investor that it
has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent,
broker or finder engaged by the Company in connection with the transactions contemplated hereby. The Company shall be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder
relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold the Investor harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys&#146; fees and out of pocket
expenses) arising in connection with any such claim. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) <U>No Strict Construction</U>. The language used in this
Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m) <U>Remedies, Other Obligations, Breaches and Injunctive Relief</U>. The Investor&#146;s remedies provided in this
Agreement, including, without limitation, the Investor&#146;s remedies provided in Section&nbsp;9, shall be cumulative and in addition to all other remedies available to the Investor under this Agreement, at law or in equity (including a decree of
specific performance and/or other injunctive relief), no remedy of the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit the Investor&#146;s right to pursue
actual damages for any failure by the Company to comply with the terms of this Agreement. The parties acknowledges that a breach by any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
party of its obligations hereunder will cause irreparable harm to the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party and that the remedy at law for any such breach may be inadequate.
The parties therefore agree that, in the event of any such breach or threatened breach, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party shall be entitled, in addition to all other available remedies, to an injunction restraining any
breach, without the necessity of showing economic loss and without any bond or other security being required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n) <U>Enforcement
Costs</U>. If: (i)&nbsp;this Agreement is placed by the Investor or the Company in the hands of an attorney for enforcement or is enforced by the Investor or the Company through any legal proceeding; (ii)&nbsp;an attorney is retained to represent
the Investor or the Company in any bankruptcy, reorganization, receivership or other proceedings affecting creditors&#146; rights and involving a claim under this Agreement; or (iii)&nbsp;an attorney is retained to represent the Investor or the
Company in any other proceedings whatsoever in connection with this Agreement, then the party against which redress is sought under this sectionshall pay all reasonable costs and expenses including reasonable attorneys&#146; fees incurred in
connection therewith to the party incurring such costs and expenses, as incurred in addition to all other amounts due hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(o)
<U>Amendment and Waiver; Failure or Indulgence Not Waiver</U>. No provision of this Agreement may be amended or waived by the parties from and after the date that is one (1)&nbsp;Business Day immediately preceding the initial filing of the
Registration Statement with the SEC. Subject to the immediately preceding sentence, (i)&nbsp;no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto and (ii)&nbsp;no provision of this Agreement
may be waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>** Signature Page Follows ** </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF,</B> the Investor and the Company have caused this
Agreement to be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>THE COMPANY:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: VP&nbsp;&amp; Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTOR:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LINCOLN PARK CAPITAL FUND, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: LINCOLN PARK CAPITAL, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: ROCKLEDGE CAPITAL CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Josh Scheinfeld</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Josh Scheinfeld</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: President</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBITS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Officer&#146;s Certificate</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Secretary&#146;s Certificate</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Letter to Transfer Agent</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF OFFICER&#146;S CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Officer&#146;s Certificate (&#147;<B>Certificate</B>&#148;) is being delivered pursuant to
<U>Section</U><U></U><U>&nbsp;8(e)</U> of that certain Purchase Agreement dated as of August&nbsp;2, 2022, (&#147;<B>Purchase Agreement</B>&#148;), by and between<B> PLUS THERAPEUTICS, INC.</B>, a Delaware corporation (the
&#147;<B>Company</B>&#148;), and <B>LINCOLN PARK CAPITAL FUND, LLC </B>(the &#147;<B>Investor</B>&#148;). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned, ___________, ______________ of the Company, hereby certifies, on behalf of the Company and not in his
individual capacity, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. I am the _____________ of the Company and make the statements
contained in this Certificate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. The representations and warranties of the Company contained in the
Purchase Agreement are true and correct in all material respects (except to the extent that any of such representations and warranties is already qualified as to materiality in Section&nbsp;4 of the Purchase Agreement, in which case, such
representations and warranties are true and correct without further qualification) as of the date when made and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, in
which case such representations and warranties are true and correct as of such date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. The Company has
performed, satisfied and complied in all material respects with covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection
pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is
generally able to pay its debts as they become due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, I have hereunder signed my name on this ___ day
of ___________. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned as Secretary of <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation,
hereby certifies that ___________ is the duly elected, appointed, qualified and acting ________ of <B>PLUS THERAPEUTICS, INC.</B> and that the signature appearing above is his genuine signature. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Secretary</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SECRETARY&#146;S CERTIFICATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Secretary&#146;s Certificate (&#147;Certificate&#148;) is being delivered pursuant to
<U>Section</U><U></U><U>&nbsp;8(k)</U> of that certain Purchase Agreement dated as of August&nbsp;2, 2022 (&#147;Purchase Agreement&#148;), by and between <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation (the &#147;Company&#148;) and
<B>LINCOLN PARK CAPITAL FUND, LLC</B> (the &#147;Investor&#148;), pursuant to which the Company may sell to the Investor up to Fifty Million Dollars ($50,000,000) of the Company&#146;s Common Stock, $0.001 par value per share (the &#147;Common
Stock&#148;). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, Secretary of the Company, hereby certifies, on behalf of the Company and not in his individual capacity, as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. I am the Secretary of the Company and make the statements contained in this Secretary&#146;s
Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. Attached hereto as <U>Exhibit A</U> and <U>Exhibit B</U> are true, correct and complete
copies of the Company&#146;s bylaws (&#147;Bylaws&#148;) and Certificate of Incorporation (&#147;Charter&#148;), in each case, as amended through the date hereof, and no action has been taken by the Company, its directors, officers or stockholders,
in contemplation of the filing of any further amendment relating to or affecting the Bylaws or Charter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.
Attached hereto as <U>Exhibit C</U> are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company on
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, at which a quorum was present and acting throughout. Such resolutions have not been amended,
modified or rescinded and remain in full force and effect and such resolutions are the only resolutions adopted by the Company&#146;s Board of Directors, or any committee thereof, or the stockholders of the Company relating to or affecting
(i)&nbsp;the entering into and performance of the Purchase Agreement, the Registration Rights Agreement and the other Transaction Documents, or the issuance, offering and sale of the Purchase Shares and the Commitment Shares, and (ii)&nbsp;and the
performance of the Company of its obligations under each of the Transaction Documents as contemplated therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. As of the date hereof, the authorized, issued and reserved capital stock of the Company is as set forth on
<U>Exhibit D</U> hereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, I have hereunder signed my name on this
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 201<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[NAME]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned as
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> of <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation, hereby
certifies that <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> is the duly elected, appointed, qualified and acting
Secretary of <B>PLUS THERAPEUTICS, INC.</B>, and that the signature appearing above is his genuine signature. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[NAME]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[TITLE]</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF LETTER TO THE TRANSFER AGENT FOR THE ISSUANCE OF THE COMMITMENT SHARES AT SIGNING OF THE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[COMPANY LETTERHEAD] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[DATE] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[TRANSFER AGENT] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Issuance of Common Stock to Lincoln Park Capital Fund, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dear <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On behalf of <B>PLUS THERAPEUTICS, INC.</B>, a Delaware corporation (the &#147;Company&#148;), you are hereby instructed to issue <B><U>as
soon as possible</U></B><B> </B>a book-entry statement representing an aggregate of 492,698 shares of our common stock in the name of <B><U>Lincoln Park Capital Fund, LLC</U></B>. The book-entry statement should be dated August&nbsp;2, 2022. The
book-entry statement should bear the following restrictive legend: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1)&nbsp;RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2)&nbsp;AN OPINION OF
HOLDER&#146;S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The book-entry statement should be sent <B><U>as soon as possible via overnight mail</U></B>
to the following address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lincoln Park Capital Fund, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">440 North Wells, Suite 410 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chicago, IL 60654 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention: Josh Scheinfeld/Jonathan Cope </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Thank you very much for your help. Please call me at ______________ if you have any questions or need anything further. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BY:_____________________________</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:3.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[name]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:3.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[title]</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d345162dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>REGISTRATION RIGHTS AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;), dated as of August&nbsp;2, 2022, by and between
<B>PLUS THERAPEUTICS, INC.</B><B>, </B>a Delaware corporation (the &#147;<U>Company</U>&#148;), and <B>LINCOLN PARK</B><B> CAPITAL FUND, LLC,</B> an Illinois limited liability company (together with it permitted assigns, the
&#147;<U>Buyer</U>&#148;). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated,
supplemented or otherwise modified from time to time, the &#147;<U>Purchase Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has agreed, upon the terms and subject to the conditions of the Purchase Agreement, to sell to the Buyer up to
Fifty Million Dollars ($50,000,000) of Purchase Shares and to induce the Buyer to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and
regulations thereunder, or any similar successor statute (collectively, the &#147;<U>Securities Act</U>&#148;), and applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE,</B> in consideration of the promises and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Buyer hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>DEFINITIONS</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. &#147;<U>Investor</U>&#148; means the Buyer, any transferee or assignee thereof to whom a Buyer assigns its rights under
this Agreement in accordance with Section&nbsp;9 and who agrees to become bound by the provisions of this Agreement, and any transferee or assignee thereof to whom a transferee or assignee assigns its rights under this Agreement in accordance with
Section&nbsp;9 and who agrees to become bound by the provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. &#147;<U>Person</U>&#148; means any
individual or entity including but not limited to any corporation, a limited liability company, an association, a partnership, an organization, a business, an individual, a governmental or political subdivision thereof or a governmental agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. &#147;<U>Register</U>,&#148; &#147;<U>registered</U>,&#148; and &#147;<U>registration</U>&#148; refer to a registration
effected by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and pursuant to Rule 415 under the Securities Act or any successor rule providing for offering securities on a continuous basis
(&#147;<U>Rule 415</U>&#148;), and the declaration or ordering of effectiveness of such registration statement(s) by the United States Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. &#147;<U>Registrable Securities</U>&#148; means all of the Commitment Shares (including all of the Initial Commitment
Shares and all of the Additional Commitment Shares) and all of the Purchase Shares that may, from time to time, be issued or become issuable to the Investor under the Purchase Agreement (without regard to any limitation or restriction on purchases),
and any and all shares of capital stock issued or issuable with respect to the Purchase Shares, the Commitment Shares<B> </B>or the Purchase Agreement as a result of any stock split, stock dividend, recapitalization, exchange or similar event or
otherwise, without regard to any limitation on purchases under the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. &#147;<U>Registration
Statement</U>&#148; means one or more registration statements of the Company covering only the resale of the Registrable Securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>REGISTRATION</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. <U>Mandatory Registration.</U> The Company shall, within thirty (30)&nbsp;Business Days after the date hereof, file with
the SEC an initial Registration Statement covering the maximum number of Registrable Securities, which shall include all of the Initial Commitment Shares and all of the Additional Commitment Shares that are issuable to the Investor pursuant to and
in accordance with Section&nbsp;5(e) of the Purchase Agreement, as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the
Investor under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the Investor in consultation with their respective legal counsel, subject to the aggregate
number of authorized shares of the Company&#146;s Common Stock then available for issuance in its Certificate of Incorporation. The initial Registration Statement shall register only the Registrable Securities. The Investor and its counsel shall
have a reasonable opportunity to review and comment upon such Registration Statement and any amendment or supplement to such Registration Statement and any related prospectus prior to its filing with the SEC, and the Company shall give due
consideration to all such comments. The Investor shall furnish all information reasonably requested by the Company for inclusion therein. The Company shall use commercially reasonable efforts to have the Registration Statement and any amendment
declared effective by the SEC at the earliest possible date. The Company shall use commercially reasonable efforts to keep the Registration Statement effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by
the Investor of all of the Registrable Securities covered thereby at all times until the date on which the Investor shall have resold all the Registrable Securities covered thereby and no Available Amount remains under the Purchase Agreement (the
&#147;<U>Registration Period</U>&#148;). The Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. <U>Rule 424 Prospectus</U>. The Company shall, as required by applicable securities regulations, from time to time file
with the SEC, pursuant to Rule 424 promulgated under the Securities Act, the prospectus and prospectus supplements, if any, to be used in connection with sales of the Registrable Securities under the Registration Statement. The Investor and its
counsel shall have a reasonable opportunity to review and comment upon such prospectus prior to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall use its reasonable best efforts to comment
upon such prospectus within one (1)&nbsp;Business Day from the date the Investor receives the final <FONT STYLE="white-space:nowrap">pre-filing</FONT> version of such prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. <U>Sufficient Number of Shares Registered</U>. In the event the number of shares available under the Registration Statement
is insufficient to cover all of the Registrable Securities, the Company shall amend the Registration Statement or file a new Registration Statement (a &#148;<U>New Registration Statement</U>&#148;), so as to cover all of such Registrable Securities
(subject to the limitations set forth in Section&nbsp;2(a)) as soon as reasonably practicable, but in any event not later than ten (10)&nbsp;Business Days after the necessity therefor arises, subject to any limits that may be imposed by the SEC
pursuant to Rule 415 under the Securities Act. The Company shall use its reasonable best efforts to cause such amendment and/or New Registration Statement to become effective as soon as reasonably practicable following the filing thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. <U>Offering</U>. If the staff of the SEC (the &#147;<U>Staff</U>&#148;) or the SEC seeks to characterize any offering
pursuant to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement to become effective and be used for resales by the Investor under Rule 415 at
then-prevailing market prices (and not fixed prices), or if after the filing of the initial Registration Statement with the SEC pursuant to Section&nbsp;2(a), the Company is otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
required by the Staff or the SEC to reduce the number of Registrable Securities included in such initial Registration Statement, then the Company shall reduce the number of Registrable Securities
to be included in such initial Registration Statement (with the prior consent, which shall not be unreasonably withheld, of the Investor and its legal counsel as to the specific Registrable Securities to be removed therefrom) until such time as the
Staff and the SEC shall so permit such Registration Statement to become effective and be used as aforesaid. In the event of any reduction in Registrable Securities pursuant to this paragraph, the Company shall file one or more New Registration
Statements in accordance with Section&nbsp;2(c) until such time as all Registrable Securities have been included in Registration Statements that have been declared effective and the prospectuses contained therein is available for use by the
Investor. Notwithstanding any provision herein or in the Purchase Agreement to the contrary, the Company&#146;s obligations to register Registrable Securities (and any related conditions to the Investor&#146;s obligations) shall be qualified as
necessary to comport with any requirement of the SEC or the Staff as addressed in this Section&nbsp;2(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>RELATED
OBLIGATIONS</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to the Registration Statement and whenever any Registrable Securities are to be registered
pursuant to Section&nbsp;2 including on any New Registration Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and,
pursuant thereto, the Company shall have the following obligations: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The Company shall prepare and file with the SEC
such amendments (including post-effective amendments) and supplements to any Registration Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the
Securities Act, as may be necessary to keep the Registration Statement or any New Registration Statement effective at all times during the Registration Period, and, during such period, comply with the provisions of the Securities Act with respect to
the disposition of all Registrable Securities of the Company covered by the Registration Statement or any New Registration Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with the intended
methods of disposition by the Investor as set forth in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. The Company shall permit the
Investor to review and comment upon the Registration Statement or any New Registration Statement and all amendments and supplements thereto at least two (2)&nbsp;Business Days prior to their filing with the SEC, and not file any such document in a
form to which Investor reasonably objects. The Investor shall use its reasonable best efforts to comment upon the Registration Statement or any New Registration Statement and any amendments or supplements thereto within two (2)&nbsp;Business Days
from the date the Investor receives the final version thereof. The Company shall furnish to the Investor, without charge any correspondence from the SEC or the staff of the SEC to the Company or its representatives relating to the Registration
Statement or any New Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. Upon request of the Investor, the Company shall furnish to the Investor,
(i)&nbsp;promptly after the same is prepared and filed with the SEC, at least one copy of such Registration Statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference and all
exhibits, (ii)&nbsp;upon the effectiveness of any Registration Statement, a copy of the prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as the Investor may reasonably
request) and (iii)&nbsp;such other documents, including copies of any preliminary or final prospectus, as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by the
Investor. For the avoidance of doubt, any filing available to the Investor via the SEC&#146;s EDGAR system shall be deemed &#147;furnished to the Investor&#148; hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. The Company shall use reasonable best efforts to (i)&nbsp;register and
qualify the Registrable Securities covered by a Registration Statement under such other securities or &#147;blue sky&#148; laws of such jurisdictions in the United States as the Investor reasonably requests, (ii)&nbsp;prepare and file in those
jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii)&nbsp;take such other
actions as may be reasonably necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv)&nbsp;take all other actions reasonably necessary or advisable to qualify the Registrable
Securities for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x)&nbsp;qualify to do business in any jurisdiction where it would not otherwise be required to
qualify but for this Section&nbsp;3(d), (y) subject itself to general taxation in any such jurisdiction, or (z)&nbsp;file a general consent to service of process in any such jurisdiction. The Company shall promptly notify the Investor who holds
Registrable Securities of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities or &#147;blue sky&#148; laws of any
jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. As promptly as practicable after becoming aware of such event or facts, the Company shall notify the Investor in writing of
the happening of any event or existence of such facts as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and promptly prepare a supplement or amendment to such Registration Statement to correct such untrue statement or
omission, and deliver a copy of such supplement or amendment to the Investor (or such other number of copies as the Investor may reasonably request). The Company shall also promptly notify the Investor in writing (i)&nbsp;when a prospectus or any
prospectus supplement or post-effective amendment has been filed, and when a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered to the Investor by email or facsimile on
the same day of such effectiveness and by overnight mail), (ii) of any request by the SEC for amendments or supplements to any Registration Statement or related prospectus or related information, and (iii)&nbsp;of the Company&#146;s reasonable
determination that a post-effective amendment to a Registration Statement would be appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. The Company shall use
its reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement, or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction and, if such
an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify the Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the
initiation or threat of any proceeding for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">g. The Company shall (i)&nbsp;cause all the Registrable
Securities to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange, or
(ii)&nbsp;secure designation and quotation of all the Registrable Securities on the Principal Market. The Company shall pay all fees and expenses in connection with satisfying its obligation under this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">h. The Company shall cooperate with the Investor to facilitate the timely issuance of the Registrable Securities to be offered
pursuant to any Registration Statement, it being agreed that such Registrable Securities shall be issued as DWAC Shares and in such denominations or amounts as the Investor may reasonably request and registered in such names as the Investor may
request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">i. The Company shall at all times provide a transfer agent and registrar
with respect to its Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">j. If reasonably requested by the Investor, the Company shall (i)&nbsp;as soon as
practicable after receipt of written notice from the Investor incorporate in a prospectus supplement or post-effective amendment such information as the Investor reasonably requests should be included therein relating to the sale and distribution of
Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities;
(ii)&nbsp;make all required filings of such prospectus supplement or post-effective amendment as soon as practicable upon notification of the matters to be incorporated in such prospectus supplement or post-effective amendment; and
(iii)&nbsp;supplement or make amendments to any Registration Statement or New Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">k. The Company
shall use its reasonable best efforts to cause the Registrable Securities covered by any Registration Statement to be registered with or approved by such other governmental agencies or authorities in the United States as may be necessary to
consummate the disposition of such Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">l. Within one (1)&nbsp;Business Day after any Registration
Statement which includes the Registrable Securities is declared effective by the SEC, the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with copies to the
Investor) confirmation that such Registration Statement has been declared effective by the SEC substantially in the form attached hereto as <U>Exhibit A</U>. Thereafter, if requested by the Buyer at any time, the Company shall require its counsel to
deliver to the Buyer a written confirmation whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not the Registration
Statement is current and available to the Buyer for sale of all of the Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">m. The Company shall take
all other reasonable actions necessary to expedite and facilitate disposition by the Investor of the Registrable Securities pursuant to any Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>OBLIGATIONS OF THE INVESTOR</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The Company shall notify the Investor in writing of the information the Company reasonably requires from the Investor in
connection with any registration statement hereunder. The Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it
as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. The Investor agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation
and filing of any registration statement hereunder and any amendments and supplements thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The Investor agrees
that, upon receipt of any notice from the Company of the happening of any event or existence of facts of the kind described in Section&nbsp;3(f) or the first sentence of 3(e), the Investor will immediately discontinue disposition of Registrable
Securities pursuant to any Registration Statement(s) covering such Registrable Securities until the Investor&#146;s receipt of the copies of a notice regarding the resolution or withdrawal of the stop order or suspension as contemplated by
Section&nbsp;3(f) or the supplemented or amended prospectus as contemplated by the first sentence of 3(e). Notwithstanding anything to the contrary, the Company shall cause its transfer agent to promptly deliver
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
shares of Common Stock without any restrictive legend in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which an
Investor has entered into a contract for sale prior to the Investor&#146;s receipt of a notice from the Company of the happening of any event of the kind described in Section&nbsp;3(f) or the first sentence of Section&nbsp;3(e) and for which the
Investor has not yet settled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>EXPENSES OF REGISTRATION</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All reasonable expenses of the Company, other than sales or brokerage commissions, incurred in connection with registrations,
filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall be paid by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>INDEMNIFICATION</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the
Investor, each Person, if any, who controls the Investor, the members, the directors, officers, partners, employees, agents, representatives of the Investor and each Person, if any, who controls the Investor within the meaning of the Securities Act
or the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;) (each, an &#147;<U>Indemnified Person</U>&#148;), against any losses, claims, damages, liabilities, judgments, fines, penalties, charges, costs, reasonable
attorneys&#146; fees, amounts paid in settlement (with the consent of the Company, such consent not to be unreasonably withheld) or reasonable expenses, joint or several, (collectively, &#147;<U>Claims</U>&#148;) incurred in investigating, preparing
or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or
not an indemnified party is or may be a party thereto (&#147;<U>Indemnified Damages</U>&#148;), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out
of or are based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact in the Registration Statement, any New Registration Statement or any post-effective amendment thereto or in any filing made in connection with the
qualification of the offering under the securities or other &#147;blue sky&#148; laws of any jurisdiction in which Registrable Securities are offered (&#147;<U>Blue Sky Filing</U>&#148;), or the omission or alleged omission to state a material fact
required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the final prospectus (as amended or supplemented, if the Company
files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein
were made, not misleading, (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to
the offer or sale of the Registrable Securities pursuant to the Registration Statement or any New Registration Statement or (iv)&nbsp;any material violation by the Company of this Agreement (the matters in the foregoing clauses (i)&nbsp;through (iv)
being, collectively, &#147;<U>Violations</U>&#148;). The Company shall reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses incurred by them in
connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section&nbsp;6(a): (i) shall not apply to a Claim by an Indemnified Person arising
out of or based upon a Violation which occurs in reliance upon and in conformity with information about the Investor furnished in writing to the Company by any Indemnified Person expressly for use in connection with the preparation of the
Registration Statement, any New Registration Statement or any such amendment thereof or supplement thereto or prospectus contained therein, if such Registration Statement, New Registration Statement or amendment thereof or supplement thereto or
prospectus contained therein was timely made available by the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pursuant to Section&nbsp;3(c) or Section&nbsp;3(e); (ii) with respect to any superseded prospectus, shall not inure to the benefit of any Indemnified Person from whom the Indemnified Person
asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any person controlling such Indemnified Person) if the untrue statement or omission of material fact contained in the superseded
prospectus was corrected in the revised prospectus, as then amended or supplemented, if such revised prospectus was timely made available by the Company pursuant to Section&nbsp;3(c) or Section&nbsp;3(e), and the Indemnified Person was promptly
advised in writing not to use the incorrect prospectus prior to the use giving rise to a violation and such Indemnified Person, notwithstanding such advice, used it; (iii)&nbsp;shall not be available to the extent such Claim is based on a failure of
the Investor to deliver or to cause to be delivered the prospectus made available by the Company, if such prospectus was timely made available by the Company pursuant to Section&nbsp;3(c) or Section&nbsp;3(e); and (iv)&nbsp;shall not apply to
amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld. Such indemnity shall remain in full force and effect regardless of any
investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. In connection with the Registration Statement or any New Registration Statement or prospectus, the Investor agrees to
indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section&nbsp;6(a), the Company, each of its directors, each of its officers who signs the Registration Statement or any New Registration Statement,
each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (collectively and together with an Indemnified Person, an &#147;<U>Indemnified Party</U>&#148;), against any Claim or Indemnified Damages to
which any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon any Violation, in each case to the extent, and only to the extent, that such
Violation occurs in reliance upon and in conformity with written information about the Investor set forth on <U>Exhibit B</U> attached hereto or updated from time to time in writing by the Investor and furnished to the Company by the Investor
expressly for use in connection with such Registration Statement or prospectus or any New Registration Statement or from the failure of the Investor to deliver or cause to be delivered the prospectus made available by the Company, if such prospectus
was timely made available by the Company pursuant to Section&nbsp;3(c) or Section&nbsp;3(e); and, subject to Section&nbsp;6(d), the Investor will reimburse any legal or other expenses reasonably incurred by any Indemnified Party in connection with
investigating or defending any such Claim; provided, however, that the indemnity agreement contained in this Section&nbsp;6(b) and the agreement with respect to contribution contained in Section&nbsp;7 shall not apply to amounts paid in settlement
of any Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably withheld; provided, further, however, that the Investor shall be liable under this Section&nbsp;6(b) for only that
amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. Promptly after receipt by an Indemnified Person or Indemnified Party under this Section&nbsp;6 of notice of the
commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this
Section&nbsp;6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be; provided, however, that an
Indemnified Person or Indemnified Party shall have the right to retain its own counsel with the fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing
interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate fully with the indemnifying party in connection with any
negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The
indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of
any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified
Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified
Person of a release from all liability in respect to such claim or litigation. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect
to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not
relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section&nbsp;6, except to the extent that the indemnifying party is prejudiced in its ability to defend such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. The indemnification required by this Section&nbsp;6 shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this Section&nbsp;6 that is later determined not to be entitled to such payment shall return such
payment to the person making it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. The indemnity agreements contained herein shall be in addition to (i)&nbsp;any cause
of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii)&nbsp;any liabilities the indemnifying party may be subject to pursuant to applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>CONTRIBUTION</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to
make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section&nbsp;6 to the fullest extent permitted by law; provided, however, that: (i)&nbsp;no seller of Registrable Securities guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii)&nbsp;contribution by any
seller of Registrable Securities shall be limited in amount to the net amount of proceeds received by such seller from the sale of such Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>REPORTS AND DISCLOSURE UNDER THE SECURITIES ACT</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With a view to making available to the Investor the benefits of Rule 144 promulgated under the Securities Act or any other
similar rule or regulation of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration (&#147;<U>Rule 144</U>&#148;), the Company agrees, at the Company&#146;s sole expense, so long as the
Investor owns Registrable Securities, to use reasonable best efforts to: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. make and keep public information available, as those terms are understood
and defined in Rule 144; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. furnish to the Investor so long as the Investor owns Registrable Securities, promptly upon request, (i)&nbsp;a written
statement by the Company that it has complied with the reporting and or disclosure provisions of Rule 144, the Securities Act and the Exchange Act, (ii)&nbsp;a copy of the most recent annual or quarterly report of the Company and such other reports
and documents so filed by the Company, and (iii)&nbsp;such other information as may be reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. take such additional action as is reasonably requested by the Investor to enable the Investor to sell the Registrable
Securities pursuant to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Company&#146;s Transfer Agent as may be reasonably requested from time to time by the
Investor and otherwise fully cooperate with Investor and Investor&#146;s broker to effect such sale of securities pursuant to Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company agrees that damages may be an inadequate remedy for any breach of the terms and provisions of this Section&nbsp;8
and that Investor shall, whether or not it is pursuing any remedies at law, be entitled to seek equitable relief in the form of a preliminary or permanent injunctions, without having to post any bond or other security, upon any breach or threatened
breach of any such terms or provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>ASSIGNMENT OF REGISTRATION RIGHTS</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the
Investor; provided, however, that any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company remains the surviving entity immediately after such transaction shall not be deemed an
assignment. The Investor may not assign its rights under this Agreement without the prior written consent of the Company, other than to an affiliate of the Investor controlled by Jonathan Cope or Josh Scheinfeld, in which case the assignee must
agree in writing to be bound by the terms and conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>AMENDMENT OF REGISTRATION RIGHTS</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No provision of this Agreement may be amended or waived by the parties from and after the date that is one Business Day
immediately preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding sentence, no provision of this Agreement may be (i)&nbsp;amended other than by a written instrument signed by both parties
hereto or (ii)&nbsp;waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in
exercising such right or remedy, shall not operate as a waiver thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>MISCELLANEOUS</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. A Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such
Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election
received from the registered owner of such Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. Any notices, consents, waivers or other
communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt, when delivered personally; (ii)&nbsp;upon receipt, when sent by facsimile or
email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii)&nbsp;one (1) Business Day after deposit with a nationally recognized overnight delivery service, in each case
properly addressed to the party to receive the same. The addresses, email addresses and facsimile numbers for such communications shall be: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to the Company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plus Therapeutics, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4200 Marathon Blvd., Suite 200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Austin, Texas 78756</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telephone:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(737) <FONT STYLE="white-space:nowrap">255-7194</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">asims@plustherapeutics.com</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew Sims</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hogan Lovells US LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">609 Main Street, Suite 4200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Houston, TX 77002</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telephone:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(713) <FONT STYLE="white-space:nowrap">632-1400</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Facsimile:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(713) <FONT STYLE="white-space:nowrap">632-1401</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">andrew.strong@hoganlovells.com</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">william.intner@hoganlovells.com</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew L. Strong</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">William I. Intner</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If to the Investor: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lincoln Park Capital Fund, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">440 North Wells, Suite 410</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chicago, IL 60654</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telephone:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(312) <FONT STYLE="white-space:nowrap">822-9300</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Facsimile:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(312) <FONT STYLE="white-space:nowrap">822-9301</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Josh Scheinfeld/Jonathan Cope</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With a copy to (which shall not constitute notice or service of process): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dorsey&nbsp;&amp; Whitney LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">51 West 52<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New York, NY 10019</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telephone:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(212) <FONT STYLE="white-space:nowrap">415-9214</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Facsimile:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(212) <FONT STYLE="white-space:nowrap">953-7201</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marsico.anthony@dorsey.com</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthony J. Marsico</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">or at such other address, email address and/or facsimile number and/or to the attention of such other
person as the recipient party has specified by written notice given to each other party three (3)&nbsp;Business Days prior to the effectiveness of such change. Written confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent,
waiver or other communication, (B)&nbsp;mechanically or electronically generated by the sender&#146;s facsimile machine or email account containing the time, date, recipient facsimile number or email address, as applicable, and an image of the first
page of such transmission or (C)&nbsp;provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or email, or receipt from a nationally recognized overnight delivery service
in accordance with clause (i), (ii) or (iii)&nbsp;above, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The corporate laws of the State of Delaware
shall govern all issues concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the
State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of and venue in the U.S. District Court for the Southern District of New York, or, if that court does not have subject matter jurisdiction, in any state court located
in the city and county of New York, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision of this Agreement shall be
invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this
Agreement in any other jurisdiction. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR
ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. This Agreement and the Purchase Agreement constitute the entire agreement
among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings among the parties hereto, other than those set forth or referred to herein and therein. This Agreement
and the Purchase Agreement supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. This Agreement is intended for the benefit of the parties hereto and any permitted successors and assigns of the Company
and, except as set forth in Section&nbsp;9, is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning
hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">g. This Agreement may be executed in two or more identical counterparts, all
of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by <FONT
STYLE="white-space:nowrap">e-mail</FONT> in a &#147;.pdf&#148; format data file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due
execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">h. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">i. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent and no rules of strict construction will be applied against any party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>** Signature Page Follows **
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF,</B> the parties have caused this Registration Rights
Agreement to be duly executed as of day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>THE COMPANY</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: VP&nbsp;&amp; Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>BUYER</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LINCOLN PARK CAPITAL FUND, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: LINCOLN PARK CAPITAL, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BY: ROCKLEDGE CAPITAL CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Josh Scheinfeld</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Josh Scheinfeld</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: President</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TO REGISTRATION RIGHTS AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF NOTICE OF EFFECTIVENESS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[Date] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>[TRANSFER AGENT]
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">___________________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">___________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Re: Plus
Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are counsel to Plus Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and have represented the
Company in connection with that certain Purchase Agreement, dated as of August&nbsp;2, 2022 (the &#147;<U>Purchase Agreement</U>&#148;), entered into by and between the Company and Lincoln Park Capital Fund, LLC (the &#147;<U>Buyer</U>&#148;),
pursuant to which the Company has issued to the Buyer an aggregate of 492,698 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;), and may in the future issue to the Buyer an aggregate of
985,396 shares of Common stock and issue and sell to the Buyer shares of Common Stock having an aggregate purchase price of up to Fifty Million Dollars ($50,000,000) in accordance with the terms of the Purchase Agreement. In connection with the
transactions contemplated by the<B> </B>Purchase Agreement, the Company has registered with the U.S. Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) the following shares of Common Stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">492,698 shares of Common Stock that have been issued to the Buyer as an initial commitment fee (the
&#147;<U>Initial Commitment Shares</U>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">985,396 shares of Common Stock to be been issued to the Buyer as an additional commitment fee (the
&#147;<U>Additional Commitment Shares</U>&#148; and, collectively with the Initial Commitment Shares, the &#147;<U>Commitment Shares</U>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">up to [__________] shares of Common Stock to be issued to the Buyer upon purchase by the Buyer from the
Company from time to time (the<B> </B>&#147;<U>Purchase Shares</U>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Purchase Agreement, the
Company also has entered into a Registration Rights Agreement, dated as of August&nbsp;2, 2022, with the Buyer (the &#147;<U>Registration Rights Agreement</U>&#148;) pursuant to which the Company agreed, among other things, to register the Purchase
Shares and the Commitment Shares under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). In connection with the Company&#146;s obligations under the Purchase Agreement and the Registration Rights Agreement, on
May&nbsp;19, 2022, the Company filed a Registration Statement (File No.&nbsp;333-[_________]) (the &#147;<U>Registration Statement</U>&#148;) with the SEC relating to the resale of the Purchase Shares and the Commitment Shares by the Buyer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the foregoing, we advise you that a member of the SEC&#146;s staff has advised us by telephone that the SEC
has entered an order declaring the Registration Statement effective under the Securities Act at [_____] [A.M./P.M.] on [__________], 202[_] and we have no knowledge, based solely on our review of the stop order notification website maintained by the
SEC, that any stop order suspending </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
its effectiveness has been issued or that any proceedings for that purpose are pending before, or threatened by, the SEC. Accordingly, the Purchase Shares and the Commitment Shares may be resold
by the Buyer under the Securities Act pursuant to the Registration Statement and may be issued without any restrictive legend or stop transfer orders maintained against them. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HOGAN LOVELLS US LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:&nbsp;_______________________________</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Lincoln Park Capital Fund, LLC </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TO REGISTRATION RIGHTS AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information About The Investor Furnished To The Company By The Investor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expressly For Use In Connection With The Registration Statement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information With Respect to Lincoln Park Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date of the Purchase Agreement, Lincoln Park Capital Fund, LLC, beneficially owned 492,698 shares of our common stock. Josh
Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC, are deemed to be beneficial owners of all of the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs.
Cope and Scheinfeld have shared voting and investment power over the shares being offered under the prospectus filed with the SEC in connection with the transactions contemplated under the Purchase Agreement. Lincoln Park Capital, LLC is not a
licensed broker dealer or an affiliate of a licensed broker dealer. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pstv-20220802.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/9/2022 1:08:06 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:pstv="http://www.plustherapeutics.com/20220802"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.plustherapeutics.com/20220802"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220802_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20220802_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pstv-20220802_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/9/2022 1:08:06 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pstv-20220802_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/9/2022 1:08:06 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pstv-20220802.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139887968454848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  02,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4200 Marathon Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PSTV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d345162d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pstv-20220802.xsd" xlink:type="simple"/>
    <context id="duration_2022-08-02_to_2022-08-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2022-08-02_to_2022-08-02"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2022-08-02_to_2022-08-02">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-08-02_to_2022-08-02"
      id="Hidden_dei_EntityCentralIndexKey">0001095981</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-08-02_to_2022-08-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-08-02_to_2022-08-02">2022-08-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-08-02_to_2022-08-02">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-08-02_to_2022-08-02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-08-02_to_2022-08-02">001-34375</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-08-02_to_2022-08-02">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-08-02_to_2022-08-02">4200 Marathon Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-08-02_to_2022-08-02">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-08-02_to_2022-08-02">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-08-02_to_2022-08-02">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-08-02_to_2022-08-02">78756</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-08-02_to_2022-08-02">(737)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-08-02_to_2022-08-02">255-7194</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-08-02_to_2022-08-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-08-02_to_2022-08-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-08-02_to_2022-08-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-08-02_to_2022-08-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-08-02_to_2022-08-02">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-08-02_to_2022-08-02">PSTV</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-08-02_to_2022-08-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "\B0A5)!Z;HJT
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M2P$"% ,4    " "\B0A5!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +R)"%4C-D6F[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M +R)"%697)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ O(D(5=J.JN)E!   *!$  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M +R)"%6?H!OPL0(  .(,   -              "  :D,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ O(D(59>*NQS     $P(   L              ( !
MA0\  %]R96QS+RYR96QS4$L! A0#%     @ O(D(51PX9>H_ 0  / (   \
M             ( !;A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +R)
M"%4D'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +R)"%5ED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d345162d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d345162d8k.htm">d345162d8k.htm</File>
    <File>d345162dex101.htm</File>
    <File>d345162dex102.htm</File>
    <File>pstv-20220802.xsd</File>
    <File>pstv-20220802_lab.xml</File>
    <File>pstv-20220802_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d345162d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d345162d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20220802_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20220802_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pstv-20220802.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "pstv",
   "nsuri": "http://www.plustherapeutics.com/20220802",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d345162d8k.htm",
      "contextRef": "duration_2022-08-02_to_2022-08-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d345162d8k.htm",
      "contextRef": "duration_2022-08-02_to_2022-08-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.plustherapeutics.com//20220802/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-22-215050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-215050-xbrl.zip
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MV*\&C2K02DC'BOO-7,?[G.DV;5&GQMG968W>QDU76B83-.OU5@U?#[@2<?-
MA8^9YH$;J7 L) ]$%#J6JEK^!'?2K)_6F\EZE).W&IBA4?OMP_N^-1837G$\
M%7+/2N:*0EFXLK,:O(T;.LH_:C9.UFS#M$@ZS(K:-J"M!YL6O_UX_W[1/,QO
MOVA:"R7WU-"7$QX"^>!([4J]66D>IP:I '%D!HJ)9=,XIRF:P,F==5M=@B*^
MM9>(U#0^KNF7IFDQP2#!EXCR!;?Q;^B$KK@\K?QZ4=./\-U$A)SA"!7Q9^0
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M&:$(I/^(TZ+^NQ8NGX(J7)%I \EJ"X-Z6V*(*7^E_;- \LF.AP;U3XXKX-T
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MY9P"K$$*UZ&H2Q+/$C,Q,>Z&SH6F*E@7M:(F<:W-T_QB;#X<HDBD563J3(\
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M%[!B=EW4!KX]AV_ 37 O_Q]02P,$%     @ O(D(5;33."*KL   9[$# !$
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M@;6_A-?!L^I\,C'/-#O*HJ-_H[XP6-ST>^.JG.H'ILEBCG]\4XQ!7GXM0)9
M1 _+R22KZF3K'\]WT]U=^K]MWDO[392<[U_6*&-3^ J\;/@Q3?ZQN[.[NY?,
MLRJYRB:+/)GG55)?HI2TY!Z_=H9?\P3Q'#Y%7Z"#J#]&DX G+JKA96:$<S$;
MP1OP^54^SJL*Q;>T8EOCB/L]^]83^6YR1F_ %^_PFY>(9:=8-/FGYG$! Y@U
M+Y[]\S/%Y-W[WTF5'+UY?WJ4HAR ?-0%S([5AJS^=-$LL@G\[2J?9;,&UW_6
M9'+\0M$!'03R (+%!S>Y*,L1B0CN33:8Y/X[6-2J?)@7\X8^EXWROQ;9\ ;?
M?GU9#"]II7%U41D./\[*ZTD^NLA'OI2VI-!\ T>&NS(& 2NOZQ?AJJL5Q$4/
M;L_6%CSZB?4,/04O^?W7;X_,LUZ_/ST\.GT,*O3M_LG9T0OSCZ7[$F[BHX0?
M\^]'NX^2@Z.W;T_V#P^/W_UL?SX[V3\P/_]^?'C^R[\?[>WN_O,1C^<4SL4-
M+/._DT?S[")_/*CR[".(#*[YB^RJ+$;RP4/SY6?_=),Z/PS^^/R?CY+?1'!@
M4:P0L>$!FFYOAU6<^Z;^A/==O>R)O]#)YRK!ETGT<CXX.CW?/WZ7'!Z].7YW
M?'[\_MW9CM7)-&CXSRG^!_>Q2TM__W><QC<@M*!HYF7->BBFDUF(B]F%Z'30
M6J"2+[.K//CS-,]F\+\B[O<YK:UL6YE!PV$^P:,/NL,JQD/XT>EC&GJ=PBT"
M5Q,HS+E<9'C(HU^?@L; A:L7H)S@DS#9#S^)38"/A9_D?\2XVAILXR](0Y1C
M7MC7BQH46EW#8&Z28CK-1P6\97*C5QP^ELWGDV)(:LP;?FNT^&&PP/ W>.7"
MUT_SBP7<<.Y[^O) U3O)P/Q)MHIM'J8HWSK'.QO^!TR+V3 'P=AP?LNLG[]'
M  :K!.#78E9,%]/DI"I@AN>7L&J7Y634DHE^[]9"D=Q")N#HP4,K/(MV5^H<
M+L'FYO&XN")# TV^9.M?S__I;)5)6>-^GV4H)#0C9\4XPZ*<;210_=X7E*C-
M%H>NVJW"/)4L!-E 9WG-:>*-V<K0VO0F'MW =V4#3]A!=_E^I7>X2GIYI.LH
ML"^DO^#!!6S[5<G+>5T5#>PL.D^X!Z'Y'1KPR:BH\&6BX>ROX6/&[*4_S!;3
M 1^&P*)-<(;%N( Y@;WEO<FSB>.SIV<D^]-R,6M R -S6QYH![55+\ @="]<
M^<BD=JY0-L)=Q<L4A3 ;PFD:97@":*<V/ -U,@.CM:ZSBE;T O5!/AXK]1^,
M)^/QD,><L0OFS@#-G.:V>D;94M]M.\F:M0Z8J*;U3B.I)#3J.\>X<_^&QFC5
M2:4IW^-!??7F_;MSB^9=%DW^N)YGP_P%^#15!O8QF&PY7"YU\>G5=_C9G]@C
M @-O,G:WS8_?[ZC[!JR3X(["W_[V^_X);1C^ -\L2D218/W1*D01^?'%T]T7
MX#9G.].=-#G*:KCI0!9@D=/E0M'O>5(!GQ:I8'\/GP"+-(!O3M KFX',#MU)
MABV8#8LYN)._9M7'O#&ZH1R/BV$!OR[GH+JVX)GHY./]Q$*-DZTRNO9D=*TG
M(2* XUA+E@-T+O:Y S6 ?@_%KX68Y7P1RXG+LVI2@)ZBS=C?3IZ]V(4EWDWF
M\25>>[!WO<1#L%#R]5:TW]M@E%NOC9&$W^%YTNU#0CQ&4ZKS&M"+G>!:+]<V
M:*#)JG>[\S\HK=.-AFN''JV-P^/?X!@+_-[O)?3_7\W9J_9!FGS:>A[^2KG=
M@QRF 6[WY#J[J1&G?_7+:7)V_/]@H$\?F4<2_/_B__Q(_\]WZ8V2.SAZ=WYT
M^F!C U8'-V4#XB.F I[BJW*RF.9T?KL0-A!"V-DN&83=[O?R3\,\QT^M<U?Q
M9?D;O1B>\@DM4SZN6P?W(:#*$;A$' H\=E!Q@QP4]WIJML,]$F/(TSK%-BB>
ME/[W];88ZMLP[20;E%<YNS7+M=YY7H$US_A?5.?YEO_ZWL[:BJ3?V\HSW!^R
M!>$;50G>!'OC;,+E##"BB0D7:W61S8K_")H(IJR)*LAO5E^ZY>SQ,*LOS94[
M*JX*L$A&*0/,8&U.B@:??)57,$3UR\2BG#58=>B*@3#/ZHPL@NT'8!'EJRPB
M;5C>HV&TW+]@!R7B7JQP%BB(M,R[3 5@7N+:$+Z&82A606QQ@=EO3:[D*>AI
MD?E^[^XGH3&,-2" =^+TB>7W," HU%1>0"J0/^T3>;&%56_)]%NV _4$>R\^
M%P84*' %RM&IKB4'XH1-;;C'D^EBTA1PV&EK0#6]5D^X^]MNM*B,(RY&^R8.
MFF?@W]5-AJL*-[!GZ:YU<ZSC+]XGL#->2SG"/6R%X>XTY.9P9%$U-\X%?+K[
MSX=POURL=[_XMM@=K2)!)ILB94K5=QQ0IRNTF7,+\&LCG'-MB(QNUU6WWA*K
ME(T;^I9OR*VG#;?NR2CK]^[6*KM/O7.I#\V(TS% Y&(;T.^M&QM+5CQI<PTT
M7!$D4^<#;H5BB?RN&2"+.S_KF2@@CE=%79I#U[988&+)^M,-+ E0#FPH>@>-
MDA;@WRD&.Q@PWUL%]^@51'5T!6=BI/:NWUNF)-R%NF*S(_#V^BE1?\\I*+95
MCLRJ^:P;(+RO@[%9I+#?NU6HL#-$/4=)'$5"U*NF'CV8:PG8+4. _5YG#'#%
M"R4<>.]B^^<FRGN3R. 7EM*_,T9(\GWK(.&*A0B,H0W#A9L\O"MR*"%IQ%7G
M';AJ2PP3+7<_!%ED7QR>-7FICY\\3F3LWY#NS]0$_=ZF >3AEPP@KZVY_7C[
M+6+)*Y[?&59>YRY:U\!Y *[OQ_4O@DWBSFM< _W>9]P#]QR"OIU<I.CR!M#6
M!'YO0ZWNI:O<[19(M9%?LBERNM(M60VD^EK#^!%KK5KB@94;K/E:BS0M8?G1
M\IPU$R[[F.3X%':&5KW"AI;7FTFF=5T0S",D%D<)DB$)XY-)V_Y0MSG\6489
M>2,72JP85IUL>4/:QNSYX62! L,'NUQH58UN0DE&4@9:E_)U!UC0PPK? <)U
M-@T,?3&+/M>J=_[K!D^J<CIEJ4TPKO*FQ&N>!R\.<-OL@C$?_KY_8)8>3:;E
M[J@8:NI,;Q;(7#&/%N*]22+'_W BQU*W/CZ +YPILT$:QT9*XX_U@N2KIKPL
MS+!\("IV_D7R"9+.=(*U;*=(9D&_M_7_/F/5UHO-K+UHFR0<W YXX?/:[X6Y
M!_\C1_8/=V3_W^V.[)=-0UA+A79F(8 V^Y:&L(FM/-G 5MX\(V$5"G,7 -_=
MQ_7+V3KV_N?D*?1[G8D*7V ^#R!/P5G;7"UQBT*'X5>0MK!*WI>G,"0/(8-A
M'?7;3F98-?';7YX1&W!C'^DKPBZF&^OC37,@5AF'GZ^3N_(A[C,X,(NN:T=,
M[_:I$5\Z5'!W21*BC#;+DG#3^VIQ]J??</:[P]G729NYRZ!1L9Z3L"R79KVS
M_P#R:OXW>1FEUKX31&G0C-@WB]@R*GD3WJ(1MX;>;7]_\VRTK.U83%GQ+S'(
MR?2'#V<?T3HI9CB8X9 EV=><+O0>1&,(N4,A&F:3X6)"LK@R1036H%Q,T"SB
M^)+O"XSR27&%H(94)CLZF%6%S=9."A<TC2VR\A,R]]M]WT F9 U4 2%B>'#P
M&,&Z9A2Q-F@L>T8$T+Z?Y<DOB]D(70JFH3F'C]1H!3H>FCTFHGD(HCW7HGV5
MP>FCF[+#22YFH'W '[Q)U^+8,5?P!>S\!4& @J)+C)!]RP%Z8:.%!BC#W<@$
M^6HYA@*9AY*]@8W2XC.XU^WXR]L.4.X7'3$^D%G.@L&C&2B>K:I$(J&1<2YG
M.2X*+ :,\1(5098,*09KC2WRZ?]:P(E F[<<B,,)VT%:'&7=L\?LCB8755G7
M+E5#QI05[<N/#EHD?.*N2]_1]S5&ZR9T0^A6<$5=+Y8^]P'L>*5V_'4V^U@M
MYLWP)GF;7;>V_+QHX&SN[:7)AYVS'="9(T;^47&:FW.<(__1A ("#:[.)+NV
M6$@%JC4?XTJ-\@'L2?T 2!!J/7\5GFH+/,QRE-TD7LID"R2 W:4Z7YHR1R]4
M $T]I-_;["ER41CD8<SZ"'$PA,=9T0UA5C!-3+N /]Z_U]BHM14<&_PF"V2W
M];LQ!^M\N*B0<X\)!'G5&D':)QGHDJ' XC4^C4^]O7[MM[N0''AJE<_+2H&!
MX6<>P,E<;/L$;P6G:3FR-7_MAG %XCUSE>/UR*J/;LND]64*\6J>P>5WU'.L
MML/?:%@O<$Y6O6/%-1B^X@$L_Y6W_+,Q.A.TG,<SD+1I9J;24A*%^SM<7S69
M;B1G>4%.QCQ#@$?NQM+]*I4/8$4 (M5@[I'/9GXB&CM,;R2=4E9H!^$G!OA*
M,N<-LUTVNRC0C"H)XX6M6!'!'Y7#!6X=)7R73=G<S#$V7F>8^8"_G.#M14CB
M7XMB3@E4QI8J<)=K\*$S(?SD1=,KELH2\5].R _,&U!3\GL\M^44+ !SB9@'
MPN!V]'(3<\)B!L8W)1;P"E@CSK#OP9^Z]BLIQJPB]!X5A'&/BVK*DBI+C',9
MY/B/SJ?A6J*-B;P.>[MB'.A+I%8!4K%=C4@L*J0 ZGST%!,D)@3YX];E'5)%
M_IO\B$-EV2*=5E0C^K'(ZYWN*=CP2II<EM?H&Z?VE:$P\X9;0^PZJUV0'\D+
MF=F4G,>+?);S]F36J!=KG+\"0@[G#GYE*PQLL@N:!W:-C'X.Y_A2F6.#'.0B
MWVPPO"^KWV-&QADAZM>78.1>7,+*)9D</#RKF3N$[2^][/=@T&;4(';9I,JS
MD84*YV#*@N!T/\ >WJ'>3K2MX0*D%YOD@K77D3AW+G&YY /!*PTQZ;B82/X0
M? !\ZSK(TU^ZB33Q*S=O;>#'ILGI!4J&W<RS!,'"(;D1G)#@/F3&6H(87$CT
M"CZF%ZL@R5%#P>L"+*T1YWJ-X !,P/+J')D9QH+S4ZA69@PJ!Y$&F;Y;X7[/
M&U;7&4R]/;"ZF!:;KP=,0<O1>TIRPK2&]C!U[):3)-*N6U=*Z"K4X15/$8US
MQN>\BRKRY)1CD)Q:(E(6+@XF^@I'[%>+;S_[AF_?';[=4C8@0U/8ZJ!&PQQE
MD4PR(JU&H;\H/4991R#:X%W*.6!MPMX52#LR&*,5HZHZ]"5&NH5O"GT5W[^]
M>:WM373D0+G&#4S)3H2;NJD0 :8L4K28\%^3 A81G"7$M!V@;5/KA.$9GN*<
M_7X/O/W[]Q8_J04X/#]HPP^PDX?@MM4%3.XF.<>Y.^9MXSDNAEAZ@.A<7N&N
MDY.X&*"X,'1HLU'[O?%BQM>F 2CD:?>_%C=Z+5S":6M-NC(94$43%.<4/T%1
MZ.SEZ"96)9C1..]IJBRI<97C=8Z0 UM)Z.AA+ 3N./L+<P=JNZ/$G%GRQ27E
MPT)E,%5,HH8+IXCGWFB0SM[@8$LUQK'(<_-K%VL5.?CN=QC+J,JN0;)AQO;8
M)%NX:-LVG(!#[O= J$3^\>%O$$;87R!@@@,[8]  K&60+)YQLO5F_^Q\.P&/
MY:+*IBVL:\Z_)_26[<EL5,YEEOBRE2*8& E\ /KG/TKDCCX-+\&)Q$J#%@K/
MB9ANM?1G41#W?GSZC-/:IVA7C1R-?K5P-B0&0\A" R,)-/)B<D&[T%@6^OL_
M@YFF=WXS*6'WURUW61%26XM(* BI_6-WY\ESXW1;G_>!A%671E!QQU.I!X!K
MJ]];S 680X]],9U:2GY1X)</8]P,HJF-EV7'3:<_P691?1#M4U@C9/>"P4E.
MI0:UF/QC;V=W]_ZE>Z"YJ]\L4"O=54"Y+7C]WOU(7B1/'7'D+@[Z9?/>#,_$
MXXL.A,-,"U,2$PDCFS&-\L;EWJ4RZ MVL?P"RO&"*GU*!+$1@&UR7<DK]2R;
MYTMY.H=;75#6B-E=9ZD_A.U] )?F4'-H_XI,"6AD[X\XQ^2(]BQJPT_-9S/Y
MK!,.3XWDZ+H,<].#B)5DOW>NA/Q0$(,TB%#"IBTF#1F'Y5R:DM3D*N2(] X,
M3HFQ49"Y&9?>F#8Z08,:.D5H-IV!(5. C545B PWV<><"MPSN)E*+&"3"B ,
M22V;)UFH/$(X3_FGX02&<T5M"?#,VKQ@?(;8%R;Y^<.,+,DS#"_RZ,&M!CLQ
MP:3H<EKP+VMGH7@3G%)X!X$?@POR6$8E?!+3S*DBC$!5_WSYIW?39;&YR6I"
M]%X%3M(+:O%81R!C%4&#=.7SU)>]538Y_WNF<]">#GRXYD0>E**9Q"/H=LC!
M^[_\:P&/P9*[$D[/A+8F1?"4)/0ZJS#@ "<54P[0'<NKJH0G3OL]^&F*7\#
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M%>Y,[C4F^TIT$S7IU;8W0;#J-*F2MY\(+5:+:<3E6#9'7A"IPQ'K:V02E!7
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M;KM=[#IB\15*XH@PF'<X)(E!$#87W8><O<-<95F;GDNJ3EX(A[QB_5:9J5Z
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M3D.OH*P6S!U#4YV(E&0G@C#O_FR&1>JG_%DXTV^0^7 EK+&W^_B_#&YA,W9
MG\"CB"V?;NY.4G<N*G3<ED([G+F%\QJ[B076;J;"$5J!0O9=HXKWF&9,^.]K
M3'6X?RLMRPSYI5#M_0K&T%P !!6(#A$-:Z^%=SCE^ZT(ZJ8.-B1#H9O,D9'L
MT(00-L.R\O.Y!7-'Q,#Q/D_5?(S$SBO)AL\\/LA6G%%*V?$.I6=GIKFAH0UT
M">\:0=")1' 2P#T=%-0.([4Q4^$DDW36&](O.5CQ%KX39DH_SBI-@=LY#"FC
M6H7+@BJX!REB_B/#0BY.C]F<%:_-9H+2EXZ?5H%N]MTAC_7]R_1@P C%93Z9
MV.WLXH0N KY[94WDF'.#:>_D4%!UF*$90^5(5\@I-KS<>_8,!'IK;[N3PO/^
M%R7G!NP'DX*9T ZS)J.IJDJ- WO+!2=_:+Y%J@U-3/.+NEF,;.(-^$VUHR=<
ME\EBC633)AA#$AN">['OQ(.PSO%*JMI#BC"LI11S$U]T# \O,$5?B./I@G -
MRLS[.J&M"(\ ?G#?851OJ4VL2H(:+!H22$J"$H<)A_Q&B@2P]C'EPD<<XD%9
M3_.&+IG&KK#"P K84;JN.9M#M=INDB=[R<'.FYW3G>0DPU3NY^#=/G\&__<]
M_-\/O-<_[#W929#H ]3OL"KF-KG(+'_J[87+MF\)1IB"2Y&<?&2;FRCL&F61
M6LK6NFU8S!>@"YN,LYS(AH9PZ)AVR+4^L@',)3NEO(]^;[G[86Z]B,FB&/X:
M760O:Y'*"<%[BUKGB0MK<N?:G"4V7TGE]B.JS.3=?RTPR,%I.5Y>@&K:Y8Y-
M8_Y$J\W;.>"HE.FN1VW6HG.FR/-5D5^[12&?]U/CDH7%U97=K'+U#@,1J#,K
MP7W%YTC8)Q,<J7S__T@BH"\\S_=VD=*6R('H;"G"&*<V+(6YXP+E[.AZSF8@
M?Z'?>W.X+R50*F"+M4TF6-OF5FO51[-=9%LKI3KM>IF<6 Y(U:G$,WSP D8,
M%NOYS?HAG;)D'.#B>#GC=K+4(S>[45-.3;21V6@07BYGAA6L,!29NA^'4JI5
M2&/C:?H0.UTOB/P 7*,Q-R*E>&6N YG[=8W\H0><!GP[@K!E\7Q;<9&J,/6J
M>+XE2U]_C1,/JE)\3OAY"C37<(3D5I!:^EQ=EJM6QHM9GZ.F6L"9.,36?@2C
M:B*_]V_V#U0]_LL6>&A1FKA'D#"+>6[J6*T3:MC)N1J?1-WF&>3^^> ^UE=9
M,>&NVT+"Q(^39?D3SD238* ; 0$I3&CE4V : %5,N':M8"KC$:'R"G&:!8J3
M' 5%TRM/N>W>X%K>OUUYP5W7?BUG^4V_]S8C"]CT1W 69'??LDZ.(+;#3>6I
M4S98H(=5 #2T&#:C=+6%+9!'JAI]S/.Y06L8A&BUQS2CHTT9\O",W'MU6:?V
M^R8LN??COW;]L"2%%W!EDHE=&+9LA!TDX.W4)6V"<\:)YB/)$.HQQK0J%;$R
MMT7VR.JKY&)1$-T;T>\1^T7JBQE).-7$VSI274:)U5.T2ENZ6R\-7/*2S<$G
M^4B<>(0DGHD4(.N>47+E6-YET@72((J]U^XV\ZFN%Y3N3^8NKP8%@O&D6+#W
M9Y [')(>?;5X\9/=;WCQW>'%GGZ*Q;:C(DXED.MW'=,&X0.PC2XO#3KX-AO
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MK85$](_ 3I@PEG,\KLHM4<0:@#,U=S;>![)&5%B3SD35W- /_FDSN3$$LVC
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M/2ZP=,D(JW8MOA)A_ .![\?-Y_;AEK?7MM5^R&:3ZX0+8RU>!8W;!T+R=J#
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MX;BOP,UU@>>6LE?XXFK8>A[D31 B2C2U)XI8 O+29R/VQB@>VU0K^Y1\=PG
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MU\&X=V%$"%Z"/_QFK-+8^VB.?_(9^ ."7]+LJE[KV.'^\$LZBC#"T30C?>I
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MZI6U#N_H%FL:#7H6#]+@9Z.U]9)HM=UBIUA%:;I\E8R-F!]%E_,]8]\&+8,
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M>2*:8QNL[=NSC'ODPFVF?CR(K/"/?X\GO80(7BE0<H.9)*BZ(_ZX,0F,"-=
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MA-TOM/W(>U,(^C"'(0S^U_W'^\/\IU!>QW5Y7,X%63VZ;-@+<<HTFKG  "<
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MX;4T"#;,A,0F>3V!YPLR"4LMK'12HL-_B238I%0A>V65H[<>G#[];W/J[TI
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M[$U6N3CVA=1-NP0G=R6WJ=O152#:K! [:HQ*)G+KJ'+O%RH<1(7%04Q9TS+
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MP/-US9CKK!V(@5>NPS/*[@(%"Z3/909;!'M 0_ )CL>$6"JPF26$ ,(3N81
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ML46F8$#B]7RU$2P@( CN.&$\P5#"THB^8837DH(L8WC[E)E13JC]F=,T'QN
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MYLA5<)":H2XP!V$W5\P_<ZQ3E_P#4$L! A0#%     @ O(D(5<R=:*H9%P
M&H0   X              ( !     &0S-#4Q-C)D.&LN:'1M4$L! A0#%
M  @ O(D(5;33."*KL   9[$# !$              ( !11<  &0S-#4Q-C)D
M97@Q,#$N:'1M4$L! A0#%     @ O(D(56(J4:AI/P  X%4! !$
M     ( !'\@  &0S-#4Q-C)D97@Q,#(N:'1M4$L! A0#%     @ O(D(52"]
MLP!( P  :@L  !$              ( !MP<! '!S='8M,C R,C X,#(N>'-D
M4$L! A0#%     @ O(D(50( W?]^!@  N48  !4              ( !+@L!
M '!S='8M,C R,C X,#)?;&%B+GAM;%!+ 0(4 Q0    ( +R)"%63";%&S00
M $\L   5              "  =\1 0!P<W1V+3(P,C(P.# R7W!R92YX;6Q0
52P4&      8 !@!_ 0  WQ8!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
